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Colon cancer progression is characterized by growth of the primary tumor in the 
colon followed by metastasis to distant organs. The metastatic cascade involves 
invasion of cells from the primary tumor into the surrounding tissue, entering 
into and survival of cancer cells in the circulation, arrival at the end organ and 
finally colonization of the end organ. The liver is the primary site of colon cancer 
metastatic colonization, with over 70% of colon cancer patients experiencing liver 
metastases. Despite current standard-of-care surgical intervention and broad-
spectra cytotoxic chemotherapeutics, the survival rate of patients with metastatic 
disease is less then 5%. A greater understanding of the biology and molecular 
determinants of liver colonization is therefore of great importance to the 
scientific and clinical community.  This thesis presents unbiased approaches to 
identify regulators of liver metastasis in colon cancer and the elucidation of the 
mechanisms involved. 
The first part of this thesis describes the identification of two microRNAs, miR-
483-5p and miR-551a as suppressors of liver metastasis by human colon cancer 
cells using two parallel, complementary xenograft models of colon cancer 
metastasis. The first approach involved a functional library-based in vivo screen
of 661 microRNAs. The second approach utilized in vivo selection of liver-
metastatic colon cancer cell population from poorly metastatic parental 
population. Functional studies revealed both microRNAs to target a common 
downstream effector gene, Creatine Kinase Brain (CKB).  
CKB was found to promote metastasis and the second part of this thesis present 
mechanistic studies that describe CKB-mediated modulation of intra- and extra-
cellular energetics by colon cancer cells that contributed to colon cancer cell 
survival in the liver microenvironment, allowing for development of macro-
metastases and finally liver colonization. Further investigation identified the 
membrane transporter SLC6a8 as an important effector of the CKB pathway and 
also a promoter of colon cancer metastasis. 
The final part of this study reveals miR-483-5p, miR-551a, CKB and SLC6a8 to be 
clinically relevant across multiple patient datasets and archival patient samples. 
MiR-483-5p and miR-551a were found to be down-regulated in liver metastases 
of patients relative to primary tumors, while CKB and SLC6a8 were up-regulated. 
In addition, proof-of-principle therapeutic experiments involving adeno-
associated viral delivery of the microRNAs and small molecule inhibition of CKB 
and SLC6a8 demonstrated the therapeutic potential of targeting this pathway in 
suppressing colon cancer metastasis. 
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CHAPTER I: Introduction 
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Colorectal cancer: Epidemiology, staging and prognosis 
Colorectal cancer (CRC) is the third most common type of cancer and one of the 
leading contributors to cancer mortality in the United States. It is the third most 
common type of cancer for both genders, behind lung cancers and gender-
specific breast and prostate cancers. Every year, there are over 160,000 newly 
diagnosed cases of colorectal cancer, with about 50,000 colorectal cancer patients 
dying from the disease (Jemal et al., 2011; Siegel et al., 2014b).  
Colorectal cancer progresses through several stages (I-IV) that, without early 
diagnosis and medical intervention, can lead to metastatic disease, the primary 
cause of mortality (Fig. 1.1). Staging of colorectal cancer is determined by the 
extent of primary tumor growth (T), the presence of cancer cells in regional 
lymph nodes (N) and the presence of distal metastases. Precancerous lesions, 
otherwise known as polyps, can be removed during colonoscopy. Localized non-
invasive tumors that had not grown beyond the muscularis priopia of the colon 
(stage I) and invasive primary tumors (stage II) without lymph nodes 
involvement can be surgically resected with high curative rates of 93% and 78% 
respectively. Disease that had progressed to stage III, which involves spread to 
regional lymph nodes, is treatable with surgery and adjuvant chemotherapy and 
is highly curable; stage III patients who undergo treatment have a 64% five-year 
survival rate. Despite current systemic chemotherapy and targeted therapy, the 
prognosis for patients with stage IV metastatic disease is poor, with five-year 
survival rate of approximately 5-7% (Siegel et al., 2014a). There is therefore an 
urgent need to identify therapeutically targetable pathways that drive colorectal 
cancer metastasis. 
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Figure 1.1 | Stages of colorectal cancer progression. Localized non-invasive 
tumors and invasive primary tumors can be cured by surgical resection. Patients 
with regional lymph node metastases (Stage III) have relatively good prognosis 
compared to patients with Stage IV diseases, which involves distal organ 
metastases (<7% five-year survival rate). 
Colorectal cancer: Therapeutic intervention 
The mainstay of current colorectal cancer chemotherapy is 5’-fluorouracil, a 
fluorinated uracil that acts through inhibition of thymidylate synthase, the rate-
limiting enzyme for pyrimidine nucleotide synthesis. In combination with 
leucovorin, which stabilizes the binding of 5’-fluorouracil to thymidylate 
synthase, 5’-fluorouracil has been shown to prolong median survival in patients 
about two-fold, from 6 months to almost a year (Moertel, 1994). Two other 
cytotoxic drugs, Irinotecan and Oxaliplatin have also been utilized in colorectal 
cancer chemotherapy. Like 5’-fluorouracil, the two drugs act by perturbing 
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nucleic acid homeostasis, but through different mechanisms. Irinotecan stabilizes 
DNA breaks caused by DNA topoisomerase I during DNA replication and 
transcription. The accumulation of such breaks results in cell death arising from 
activation of DNA damage checkpoints. Oxaliplatin is a platinum derivative that 
forms adducts with DNA, which again results in activation of DNA damage 
response pathways and subsequent cell death. Clinical trials have demonstrated 
that combinations of the above drugs in therapeutic regimes such as FOLFOX (a 
regime consisting of 5’fluorouracil, Leucovorin and Oxaliplatin) or FOLFIRI (5’-
fluorouracil, Leucovorin and Irinotecan) resulted in patients with metastatic 
disease having median survival times of approximately 20 months as compared 
to 6 months without treatment (Meyerhardt and Mayer, 2005).   
Regardless of the treatment regime used, patients diagnosed with metastatic 
colorectal cancer have a poor prognosis; 5-year survival rates for such patients 
are around 5%. The dependence of patients on chemotherapeutic agents that 
have been around for decades—5’-fluorouracil was first synthesized in 1957 
(Heidelberger et al., 1957), Oxaliplatin in 1976 (Kidani et al., 1976) and Irinotecan 
in 1987 (Kunimoto et al., 1987)—and yet only provide modest survival benefits 
that are accompanied by toxic side effects highlight the urgent need for more 
effective targeted therapies with diminished side effects. 
In recent years, identification of epidermal growth factor receptor (EGFR) as a 
receptor that is over-expressed in colorectal cancer has led to the development of 
small molecule inhibitors of EGFR (Erlotinib and Gefitinib) as well as inhibitory 
monoclonal antibodies (Cetuximab and Panitumumab). When such antagonists 
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of EGFR activity are used in clinical trials with or without Irinotecan or 
Oxaliplatin, patient response was observed with improved quality of life. 
Although there is statistically significant increase in overall survival of patients 
with metastatic disease, the increase in survival is typically modest, between 6 
months to a year, and limited to patients with KRAS wild-type disease 
(Bokemeyer et al., 2009; Van Cutsem et al., 2009). 
Given the relative lack of clinical progress in the treatment of metastatic 
colorectal cancer, there is an urgent need for a better understanding of the 
pathogenesis of colorectal cancer metastasis to identify targetable nodes in 
metastatic pathways. As the liver is the main site of colorectal cancer 
metastasis—over 70% of patients that developed metastatic disease will present 
with liver lesions, an understanding of the biology that governs colorectal cancer 
cells metastatic colonization of the liver could lead to the development of 
therapeutics targeting this important stage of colorectal cancer progression that 
are more effective then currently available therapies.  
Colorectal Cancer: Origins and progression 
Pathophysiology
Colorectal cancer arises from the lower gastrointestinal tract, which is comprised 
of the cecum, the colon and the rectum and initiates in the mucosa, the innermost 
lining of the gastrointestinal tract. Colorectal cancer begins as pre-cancerous 
lesions called polyps that project above the mucosa of the intestinal tract. The 
majority of polyps in the intestinal tracts are from non-glandular epithelium and 
are small and hyperplastic and usually do not develop into pre-cancerous lesions. 
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Adenomatous polyps are the important precursors of colorectal cancer and arise 
from the glandular epithelium of the colon and rectum. Such polyps are usually 
larger then ten millimeters in size and if not detected and removed during 
colonoscopy, can further progress to display severe dysplasia and before 
progression into adenocarcinoma and subsequent invasion through the mucosa 
of the colon and into surrounding tissues. 
Molecular determinants of colorectal cancer tumorigenesis 
As with its pathophysiology, the molecular determinants of colorectal cancer 
tumorigenesis are well understood. Seminal work by Vogelstein and others had 
identified genes and pathways which, when dysregulated progressively in the 
colonic epithelium, results in formation of adenomas and subsequently colorectal 
cancer (Fig. 1.2) (Fearon and Vogelstein, 1990). Key pathways that are 
deregulated during colorectal cancer tumorigenesis include but are not limited to 
the APC tumor suppressor pathway (Kinzler and Vogelstein, 1996), the KRAS 
oncogenic pathway (Fang and Richardson, 2005) and the p53 tumor suppressor 
pathway (Hollstein et al., 1991). 
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Figure 1.2 | Molecular basis of colorectal cancer tumorigenesis. Colorectal 
cancer tumorigenesis is marked by distinct mutational inactivation of tumor 
suppressors and activation of oncogenes leading to loss of cellular checkpoints 
and activation of oncogenic pathways. After tumorigenesis, further 
dysregulation of pathways contributes to metastatic progression. 
Constitutive activation of the Wnt pathway, achieved through inactivating 
mutations of APC or activating mutation of its degradative target, β-catenin is 
widely recognized as the initiating event prior to adenoma formation, with over 
80% of sporadic colorectal adenomas and cancers found to have aberrations in 
this pathway (Bienz and Clevers, 2000).  
Another oncogenic pathway that is frequently activated in colorectal cancer 
tumorigenesis is the mitogen activated protein kinase (MAPK) signaling 
pathway. Constitutive activation of MAPK signaling in colorectal cancer results 
from activating mutations in KRAS (Bos et al., 1987; Forrester et al., 1987) or its 
downstream effector BRAF (Rajagopalan et al., 2002; Wan et al., 2004). Such 
oncogenic mutations are commonly found in polyps and adenomas and indicate 
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a substantial role of this pathway in the early stages of colorectal cancer 
tumorigenesis (Fang and Richardson, 2005). 
An important and relatively late step in colorectal cancer formation is the 
inactivation of the p53 tumor suppressor pathway. The inactivation of the 
pathway through missense mutations or chromosomal deletion leads to loss of 
critical cellular checks against oncogenic stresses. This prevents activation of cell-
cycle arrest checkpoints or initiation of the apoptotic cascade as a result of 
cellular stresses, contributing to carcinogenesis (Rodrigues et al., 1990). 
In addition to the above-mentioned pathways, mutations in other regulatory 
pathways such as those mediated by phosphatidylinositol 3-kinase and PTEN 
(Yuan and Cantley, 2008), as well as the TGF-β tumor suppressor pathway 
(Wakefield and Roberts, 2002) have been described to occur and contribute in 
varying frequencies during colorectal cancer development. Besides these classical 
pathways, the advent of high-throughput sequencing and whole genome 
sequencing of colorectal cancer samples have led to the identification of 
additional somatic mutations that are putative drivers of colorectal cancer 
tumorigenesis (Kandoth et al., 2013; Network, 2012). However, much work 
remains with regards to functional characterization of putative driver genes 
identified by whole genome sequencing. 
Besides the above-mentioned dysregulated pathways in colorectal cancer 
tumorigenesis, there is a subgroup of patients who possess deficiencies in DNA 
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mismatch repair as a result of inactivation of the genes involved. Mismatch 
repair genes that are commonly inactivated in these patients include MLH1,
MSH2 and MSH6. The inactivation of these genes results in colorectal cancers
that are characterized as microsatellite instable (MSI) in which sizes of repetitive 
DNA elements in the genome are frequently altered (Thibodeau et al., 1998). It is 
not uncommon for these patients to have inactivation of other tumor suppressor 
genes as a result of DNA repair deficiency. MYH, another DNA repair gene
involved in base-excision repair of nucleotides, is also inactivated in certain 
colorectal cancer patients (Al-Tassan et al., 2002). 
The metastatic cascade in colorectal cancer 
Metastasis during colorectal cancer progression is a complex multi-step process 
during which the primary tumor on the surface of the mucosa develops an 
invasive front that invades through the mucosa and into the underlying 
submucosa of the colonic tract. The submucosa is richly supplied by blood 
vessels and is also responsible for the draining of blood carrying nutrients 
absorbed by the colon into the portal circulation towards the liver.  Once the 
primary tumor invades into the submucosa and surrounding circulatory vessels, 
shedding of cancer cells from the primary tumor into the circulation will result in 
dissemination of cancer cells towards distal organs (Fig. 1.3) (Gupta and 
Massagué, 2006; Nguyen et al., 2009). Upon arrival at the distal organ, the 
majority of disseminated cancer cells will undergo cell death as a result of 
inability to adapt to a new microenvironment (Chambers et al., 2002). As the 
liver is the first major organ encountered by the portal circulation, it is the main 
organ of colon cancer cell dissemination (Weiss et al., 1986). Cells that survive in 
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the liver microenvironment might undergo a period of dormancy that can last 
from several months to years. Clinically, patients have been found to have 
substantial numbers of circulating tumor cells, as well as disseminated colon 
cancer cells in the liver. However, only a small fraction of disseminated cells go 
on to develop macroscopic metastases as majority of cells die without forming 
macro-metastases (Sugarbaker, 1993). Given such evidence, in colorectal cancer, 
the rate-limiting step of liver metastases appears to be that of liver colonization. 
It is therefore of great scientific and clinical value to understand the molecular 
mechanisms that drive this process. 
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Figure 1.3 | The metastatic cascade. During metastasis, cells disseminate from 
the primary tumors and invade into the circulatory system. Cells that survive 
dissemination in circulation and arrive at distal organs have to adapt and survive 
within the foreign microenvironment before they can proliferate and colonize the 
distal organ. Colonization of distal organs and subsequent organ failure is a 
significant cause of patient mortality. 
Molecular determinants of colorectal cancer metastasis 
Given the complexity of the metastatic cascade, it is of little surprise that 
identified pathways involved in colorectal progression from the primary tumor 
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to distal metastasis are more diverse. Unlike primary tumorigenesis, mutational 
inactivation of specific metastasis-suppressing genes or activation of metastasis 
promoting genes is rare and comparative sequencing of matched primary tumors 
and metastases from the same patient have not identified many mutations 
responsible for metastatic progression (Brannon et al., 2014; Jones et al., 2008). 
However, gene expression analyses followed by experimental studies have 
identified some of the pathways involved in various steps of the metastatic 
cascade during colorectal cancer metastasis. 
Gene expression changes during colorectal cancer progression and metastasis 
can be brought about through various means, including but not limited to 
chromatin aberrations such as re-arrangements, amplifications or deletions. DNA 
hypermethylation or hypomethylation in the promoter region of genes can cause 
down-regulation or up-regulation of gene expression, respectively, and have 
been reported in colon cancer (Markowitz and Bertagnolli, 2009). More recently, 
post-transcriptional regulation of gene expression has been a subject of intense 
scrutiny (Licatalosi and Darnell, 2010; Schwanhäusser et al., 2011). 
A class of short noncoding RNAs known as microRNAs can mediate post-
transcriptional modulation of mRNA stability and translation with 
corresponding changes in gene expression. The biogenesis of mature microRNAs 
is well understood (Ha and Kim, 2014). A primary microRNA transcript (pri-
miRNA) is first transcribed by RNA polymerase II, and occasionally RNA 
polymerase III. Subsequently, pri-miRNA transcripts are cleaved by the 
ribonuclease Drosha, to form pre-miRNA stem-loop transcripts that are then 
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exported into the cytoplasm where they are recognized and cleaved by a second 
ribonuclease, Dicer, to form short 21-26 nucleotide miRNA-duplexes. These 
duplexes are loaded onto the RNA-induced silencing (RISC) complex, with the 
subsequent release of the passenger non-targeting microRNA strand. The RISC 
complex bearing a mature single-stranded miRNA will bind to target mRNAs 
bearing sequences complementary to the bound miRNA and recruit effector 
proteins responsible for initiating the decay or translational repression of the 
target mRNA. Target sequences of microRNAs are usually present on the 3’-UTR, 
and occasionally coding sequences (CDS) of the mRNA transcript. 
In recent years, as with identification of genes and pathways involved in primary 
tumorigenesis, microRNAs that regulate tumorigenesis have also been identified 
and their downstream effector genes and pathways well established (Schickel et 
al., 2008). In addition to the numerous studies identifying microRNAs that 
regulate overt tumorigenic phenotypes such as proliferation and apoptosis, and 
early stages of the metastatic cascade such as invasion and migration, 
microRNAs involved in later stages of metastasis such as lung colonization by 
breast cancer and melanoma cells have been described (Pencheva et al., 2012; Png 
et al., 2012). The relative lack of studies investigating and identifying genes and 
microRNAs involved in liver colonization is in part due to a lack of defined 
experimental models that specifically examine liver colonization by colon cancer 
cells without involving other aspects of the metastatic cascade such as invasion 
into circulation, survival during dissemination and extravasation into the liver 
parenchyma. 
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Given the importance of liver colonization as a rate-limiting step in the 
culmination of the metastatic cascade, it would be of scientific interest develop a 
model of colon cancer liver colonization that can be utilized to identify 
microRNAs that regulate liver colonization. Clinically, identification of 
microRNAs and downstream pathways that suppress liver metastasis can 
potentially lead to development of therapeutics that suppress liver metastasis, 
either by therapeutic delivery of the microRNAs or inhibition of their effector 
genes. Availability of such therapeutics, alongside currently available drugs can 
potentially lead to better outcomes for patients. 
Colorectal cancer: In vivo experimental models
Mouse models of colorectal cancer tumorigenesis 
The tumorigenic process of colorectal cancer is well defined and consequently, 
genetic mouse models of colorectal cancer tumorigenesis with mutations of key 
oncogenic or tumor suppressor genes have been established (Karim and Huso, 
2013). 
Considering the significance of APC as a gatekeeper to colon tissue integrity and 
inactivation of APC as an initiating event in formation of most adenomas, the 
most common types of genetic mouse models of colorectal cancer tumorigenesis 
is the APC mutant mouse or the β-catenin mutant mice that regulate the Wnt 
signaling pathway downstream of APC. 
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APC mutant mice with various inactivating mutations of the APC tumor 
suppressor genes have been generated. Loss of APC activity results in formation 
of polyps. However the polyps themselves do not progress to aggressive 
adenocarcinoma (Moser et al., 1990). Similarly, activating stabilizing mutations of 
β-catenin downstream of APC regulation results in the formation of polyps that 
do not progress to malignancy. Based on the work of Vogelstein and others in 
defining the molecular progression of colorectal cancer tumorigenesis, APC or β-
catenin mutant mice with mutations in other oncogenic and tumor suppressors 
genes have also been generated. 
APC mutant mice with genetic alterations in other genes have been observed to 
exhibit progression of colonic polyps to adenomas and adenocarcinomas. In 
particular, abrogation of the TGF-β tumor suppressor pathway through mutation 
of SMAD4 in APC mutant mice resulted in development of invasive 
adenocarcinomas (Takaku et al., 1998). 
In addition to genetic mouse models developed through abrogation of APC 
tumor suppressor pathways and synergistic mutation of oncogenes and/or 
suppressors, genetic mouse models that involve perturbation of the mismatch 
repairs system were also developed which also resulted in the onset of adenomas 
in the gastrointestinal tracts of the mice (de Wind et al., 1999). 
Despite the numerous genetic mouse models of colorectal cancer tumorigenesis, 
a common caveat for all of the above-mentioned models is the lack of cancer 
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progression beyond the primary site. It is not surprising that these genetic mouse 
models rarely develop distal metastases (Nandan and Yang, 2010), given the 
shorter lifespan of the above-described mice due to heavy primary tumor burden. 
As metastasis to distal organs such as the liver and lungs are responsible for the 
majority of colon cancer deaths in human patients, in vivo mouse models of
metastasis that are complementary to available genetic models of tumorigenesis 
have to be developed and utilized to study the metastatic cascade and potential 
therapeutic applications (Francia et al., 2011). 
Mouse models of colorectal cancer metastasis 
In order to study colon cancer metastasis in vivo with human colon cancer cells,
xenograft mouse models in which cells are implanted or injected into 
immunodeficient mice are developed. Depending on the stage(s) of the 
metastatic cascade that are under investigation, investigators have transplanted 
or inoculated cells into mice at various sites. 
To model the progression of colon cancer cells from the primary site to 
metastasis of distal organs, intra-cecal injections of colon cancer cells or 
implantation of small tumor fragments onto the cecum of nude mice have been 
performed (Morikawa et al., 1988a). Mice inoculated with colon cancer through 
these means went on to develop metastases at local and regional lymph nodes as 
well as distal organs such as the liver and lungs, demonstrating the 
recapitulation of the entire metastatic cascade. 
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Besides inoculation of colon cancer at orthotopic sites, direct introduction of 
colon cancer cells into the circulation have been performed through portal vein 
injection or intrasplenic injection, both of which result in dissemination of colon 
cancer cells into the portal circulation and into the liver parenchyma (Morikawa 
et al., 1988b). Compared to intra-cecal injection, these procedures bypass the 
earlier stages of the metastatic cascade such as invasion of the primary tumor 
and intravasation into the circulation. Instead, survival of colon cancer cells in 
the circulation and later stages are examined.  
Regardless of which stage of the metastatic cascade is under investigation, 
xenograft models of colon cancer metastasis have proven of great utility in 
delineating the mechanisms involved in metastasis as in vivo modeling of
colorectal cancer progression can provide insights that are not readily apparent 
in in vitro systems. A criticism of xenograft models of human colon cancer cell
metastasis is that immunodeficient mice are used, which do not allow for study 
of the interactions between the immune system and cancer cells. To address this 
concern, it is possible to utilize xenograft models using mouse cancer cells 
implanted into syngeneic mice. However, currently available mouse colon cell-
lines are limited to those derived from chemical carcinogenesis which might not 
necessarily represent the common etiology of human colon cancers (Griswold 
and Corbett, 1975). Eventually, derivation of mouse cell-lines from primary 
tumors arising from genetic mouse models of colorectal cancer for use in 
xenograft experimental systems can allow for better interrogation of the 
metastatic cascade in an immuno-competent setting. 
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In vivo selection of metastatic phenotypes 
In vivo selection of cancer cells is a technique pioneered by Fidler and colleagues
in 1973 (Fig. 1.4) (Fidler, 1973). It can be utilized to enrich for specific cell 
populations with desired phenotypes from more heterogeneous populations. 
Within the context of cancer biology, in vivo selection had been utilized to select
for breast cancer cells with enhanced capacity for lung, bone and brain metastasis. 
Transcriptomic profiling and mechanistic studies comparing the parental 
heterogeneous breast cancer population and the in vivo selected organ-metastatic
derivatives had resulted in the identification of genes that regulate metastasis to 
the respective organs by breast cancer cells (Kang et al., 2003; Minn et al., 2005; 
Png et al., 2012; Tavazoie et al., 2008). More recently, in vivo selection was
performed with melanoma cells and mediators of melanoma metastasis to the 
lungs were identified (Pencheva et al., 2012). Similar cellular phenotypes were 
identified in breast and melanoma cancer cells that were in vivo selected for lung
colonization capacity, although different genes and pathways were utilized in 
breast cancer and melanoma respectively (Pencheva et al., 2012; Png et al., 2012). 
This highlights the possibility that with regards to organ colonization, there 
might be common phenotypes that are selected for irrespective of cancer type. 
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Figure 1.4 | In vivo selection. During in vivo selection, a heterogeneous
population of cancer cells is inoculated into specific organs (such as lung) in a 
mouse. The first generation metastatic nodule that forms can be excised, 
dissociated into cells and the process repeated. Over several iterations, a more 
metastatic population of cells can be selected for. 
With regards to colorectal cancer, an in vivo selection model for liver colonization,
the final step of metastasis has not been yet been demonstrated. Given the utility 
of in vivo selection for identifying molecular mediators of breast and lung cancer
metastasis, novel mediators of colorectal cancer metastasis can be identified with 
an appropriate model of liver colonization and in vivo selection.
Specific aims 
This thesis aims to identify molecular determinants of colorectal cancer 
metastasis to the liver, the primary site of colorectal cancer metastasis. The first 
part of the thesis will describe two complementary approaches used to identify 
microRNAs that suppress liver colonization and metastasis by colon cancer cells. 
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The first approach is an in vivo microRNA library screen using multiple colon
cancer cell-lines with distinct mutational spectrum. The second approach 
harnesses in vivo selection of colon cancer cells to identify endogenous
microRNAs that suppress colon cancer liver colonization. The complementary 
approaches led to the identification of miR-483-5p and miR-551a as suppressors 
of colon cancer metastasis and colonization (Chapter II). Functional 
characterization of both microRNAs was performed and an organotypic slice 
culture system was developed to allow for phenotypic characterization of the 
microRNAs in vitro.
Following the identification of miR-483-5p and miR-551a, unbiased 
transcriptomic profiling approaches were used to identify downstream targets 
and effectors of both microRNAs. One gene, Creatine Kinase Brain (CKB), was 
identified to phenocopy the effects of the microRNAs and further mechanistic 
dissection of CKB-mediated pathways identified it as a pro-survival factor in the 
hypoxic liver microenvironment of colon cancer metastases through modulation 
of intra- and extra-cellular energetics. Other components of the creatine kinase 
axis during colon cancer metastasis to the liver are also examined, leading to the 
identification of SLC6a8, a membrane channel as another critical effector in the 
creatine kinase mediated metastatic axis (Chapter III). 
In the third part of this thesis, clinical evidence is provided to support the clinical 
significance of these findings to colorectal cancer metastasis in patients (Chapter 
IV). Publicly available datasets as well as archival materials from primary tumors 
and liver metastases were interrogated to reveal the relevance of the microRNAs, 
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CKB and SLC6a8 to colon cancer liver metastasis. Given the clinical relevance of 
the pathway described, proof-of-principle therapeutic delivery of the microRNAs 
and inhibition of CKB and SLC6a8 was investigated as well. The final chapter of 
the thesis discusses the findings of this thesis and presents future directions 
(Chapter V). 
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Chapter II: Identification of Novel Molecular Determinants of Colorectal 
Cancer Metastasis to the Liver 
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As a first step to identify molecular determinants of colorectal cancer metastasis 
to the liver, this chapter describes two complementary approaches used to 
identify microRNAs that regulate colon cancer cell metastasis. The first approach 
employed a library-based gain-of-function in vivo screen of 661 microRNAs to
identify microRNAs that when over-expressed, suppressed liver colonization by 
colon cancer cells. The second approach utilizes in vivo selection to select for
highly metastatic colon cancer cells to identify endogenous microRNA 
suppressors of colon cancer metastasis. MicroRNAs that were identified and 
common to both approaches were further characterized and studied. An in vitro
organotypic slice culture system was also developed to allow for phenotypic 
study of processes regulated by the microRNAs. 
In vivo screening of microRNA library identifies suppressors of liver
colonization by colon cancer cells 
Library-based screening approaches have been previously employed to identify 
regulators of cancer progression (Mohr et al., 2010). However, most of the earlier 
studies have been performed in an in vitro setting that might not result in
identification of modulators that are active in an in vivo and more physiologically
relevant setting. 
To identify microRNAs that when over-expressed, suppress colon cancer liver 
colonization in a physiological context, a lentiviral expression library of 661 
microRNAs was used (Fig. 2.1). Heterogeneous colon cancer cell-line populations 
were infected with the lentiviral library at a low multiplicity-of-infection (MOI), 
such that each individual cell likely over-expressed a single microRNA.  
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Figure 2.1 | A lentiviral-based microRNA library screen is used to identify 
microRNAs that are potential suppressors of liver metastasis by colorectal 
cancer cells. 
Two colon cancer cell-lines, SW620 and WiDR, were used and were selected in 
part for their different known driver mutational spectrum. This allowed for 
identification of microRNAs that can suppress colon cancer liver colonization 
irrespective of their mutational backgrounds.
Following transduction, colon cancer cell-populations were intra-hepatically 
injected into immunodeficient mice to allow for selection of cells capable of 
colonizing the liver and forming metastatic liver nodules 4-6 weeks after 
injection. Genomic DNA was extracted from the resulting nodules and PCR 
amplification, reverse transcription and microRNA profiling of microRNA 
inserts allowed for quantification of changes in library-derived microRNA 
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representation in the context of liver colonization compared to a reference pool 
obtained from cell-populations that had not undergo the selective pressure of 
liver colonization (Fig. 2.1). Biological replicate screenings were performed for 
both cell-lines and significant correlation was found between pairs of biological 
replicates, indicating that the screen was reproducible (for SW620, r=0.7344, 
p<0.001; WiDR, r=0.8066, p<0.001). MicroRNAs that displayed reduced 
representation in the context of liver colonization were identified in both cell-
lines (Table 2.1) and considered to be putative suppressors of liver colonization. 
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Table 2.1 | List of microRNAs depleted after liver colonization by SW620 and 
WiDR cells transduced with the microRNA library. In vivo library screen was
performed in duplicate for both cell-lines and compared to reference samples 
comprising of cell populations transduced with the library, but not injected into 
mice. 
miRNA Fold Change vs. 
Reference 
miRNA Fold Change vs. 
Reference 
SW620 WiDR SW620 WiDR 
hsa-let-7e -1.92 -92.73 hsa-miR-384 -3.57 -5.63 
hsa-miR-009-1 -3.47 -3.79 hsa-miR-409-3p -3.27 -8.58 
hsa-miR-023a -6.11 -1.61 hsa-miR-412 -2.51 -1.92 
hsa-miR-092a -1.99 -2.91 hsa-miR-483-5p -1.71 -2 
hsa-miR-099a -4.24 -1.99 hsa-miR-509-1 -1.98 -11.25 
hsa-miR-099b -1.7 -6.35 hsa-miR-542-3p -2.09 -1.64 
hsa-miR-107 -2.43 -3.05 hsa-miR-545 -2.17 -1.61 
hsa-miR-1203 -1.79 -2.18 hsa-miR-551a -7.14 -8.07 
hsa-miR-1243 -1.61 -1.95 hsa-miR-551b -12.7 -8.97 
hsa-miR-1244 -3.52 -1.61 hsa-miR-557 -1.92 -5.27 
hsa-miR-1288 -2.61 -1.81 hsa-miR-563 -1.78 -2.43 
hsa-miR-1297 -1.74 -3.62 hsa-miR-574 -8.09 -4.33 
hsa-miR-133a -1.75 -2.8 hsa-miR-574-5p -3.18 -5.18 
hsa-miR-134 -1.99 -2.5 hsa-miR-590-5p -1.86 -2.38 
hsa-miR-138-2 -2.84 -2.99 hsa-miR-591 -1.93 -3 
hsa-miR-143 -2.58 -2.2 hsa-miR-592 -2.4 -5.36 
hsa-miR-149* -2.74 -2.05 hsa-miR-638 -2.1 -1.95 
hsa-miR-181a-2* -1.65 -1.66 hsa-miR-656 -2.02 -2.51 
hsa-miR-192 -1.67 -3.8 hsa-miR-769-5p -2.17 -1.61 
hsa-miR-196a-1 -1.92 -19.33 hsa-miR-877 -1.83 -1.87 
hsa-miR-218-1 -29.13 -17.78 hsa-miR-9* -1.96 -7.84 
hsa-miR-363 -2.37 -3.68 hsa-miR-92a-2* -1.64 -6.14 
hsa-miR-369-3p -1.83 -2.03 
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In vivo selection for liver metastatic colon cancer cells identifies endogenous
microRNAs that suppressed liver metastasis 
As a complementary approach to library-based screening, which identified 
microRNAs that when over-expressed suppressed liver colonization by colon 
cancer cells, in vivo selection was used to identify endogenously modulated
microRNAs that suppress liver metastasis. In vivo selection was performed on
the LS174T human colon cancer line, which displays MSI, for enhanced liver 
colonization activity through iterative intra-hepatic injection of cancer cells into 
immunodeficient mice followed by surgical resection of metastatic liver nodules 
and dissociation of cells (Fig. 2.2).  
Figure 2.2 | In vivo selection of LS174T human colon cancer cells. LS174T
parental cell populations expressing a luciferase reporter for bioluminescent 
imaging were injected into the liver of immunodeficient NOD-SCID mice. 
Bioluminescent imaging was used to monitor the development of metastatic 
nodules in mice. After a period of 3-4 weeks, mice were euthanized and 
established nodules excised and dissociated into cells. Dissociated cells were 
injected into mice. After three iterations of the process, two independent third-
generation liver colonizers cell populations were derived and tested for 
enhanced liver colonizing potential. 
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Independently derived third-generation liver colonizers LS-LvM3a and LS-
LvM3b displayed significantly enhanced (>50 fold) capacity for liver colonization 
(Fig. 2.3A). Importantly, these derivatives also displayed dramatically enhanced 
(>150 fold) liver metastatic capacity upon portal circulation injection in 
experimental metastasis assay—revealing the acquisition of liver colonization 
capacity to be sufficient for imparting enhanced liver metastasis activity (Fig. 
2.3B). These in vivo selected metastatic derivatives were found to display reduced
expression of endogenous microRNAs that could be suppressors of metastasis 
(Table 2.2). 
Figure 2.3 | Liver colonization is a rate-limiting step during colorectal cancer 
metastasis to the liver. A, Bioluminescence plot of liver colonization by 5 X 105 
LS-Parental, and in vivo-selected LvM3a and LvM3b cells after direct intrahepatic
injection (n>5). Each data-point represents the measurement from one mouse. 
Mice were imaged at day 21 after injection and livers extracted for ex vivo
imaging and gross morphological examination. B, Liver metastasis in mice 
injected intra-splenically with 5 X 105 LS-Parental, LvM3a and LvM3b cells. 
Metastatic progression was measured by bioluminescence imaging (n>5). Mice 
were imaged at day 21 after injection and livers extracted for gross examination. 
p values are based on one-sided Mann-Whitney test for non-Gaussian 
distribution.  **p<0.01; ***p<0.001. 
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Table 2.2 | List of miRNAs depleted in highly metastatic LS Derivatives 
compared to LS174T parental cell-line. 
miRNA Fold Change in Metastatic 
Derivatives 
hsa-miR-483-5p -11.74 
hsa-miR-429 -7.43 
hsa-miR-218-1* -6.015 
hsa-miR-551a -5.03 
hsa-miR-146a* -3.8 
hsa-miR-423-3p -3.64 
hsa-miR-499-3p -3.55 
hsa-miR-1246 -3.2 
hsa-miR-148a -3.065 
hsa-miR-20b* -3.065 
hsa-miR-155 -2.775 
hsa-let-7d* -2.715 
hsa-miR-215 -2.585 
hsa-let-7d* -2.465 
hsa-miR-7-1* -2.435 
hsa-miR-377 -2.31 
hsa-miR-2115 -2.265 
hsa-miR-7 -2.165 
hsa-miR-1231 -2.135 
hsa-miR-16-2* -2.09 
hsa-miR-200b* -2.08 
hsa-miR-211 -2.02 
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Mir-483-5p and miR-551a are robust suppressors of liver metastasis by colon 
cancer cells 
Two microRNAs, miR-483-5p and miR-551a were identified by the overlap of the 
library-based screening approach and in vivo selection to be putative suppressors
of liver metastasis (Fig. 2.4). 
Figure 2.4 | Integrative approach to identification of miR-483-5p and miR-551a 
as putative suppressors of colon cancer metastasis. microRNAs that had a loss 
of representation of at least 1.6 fold in both SW620 and WiDR cell-lines in the 
miRNA library screen (Table 2.1) and silenced at least 2 fold in metastatic 
derivatives (Table 2.2) were considered potential suppressors. 
Consistent with a suppressive role for these microRNAs in liver metastasis, over-
expression of miR-483-5p or miR-551a robustly suppressed metastasis by LS-
LvM3b cells introduced into the portal circulation (Fig. 2.5A), while inhibition of 
endogenous miR-483-5p or miR-551a in poorly metastatic colon cancer cell-lines, 
LS-174T and SW480 significantly enhanced liver metastatic colonization (Fig. 
2.5B, C). 
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Figure 2.5 | miR-483-5p and miR-551a are endogenous microRNAs that 
suppress liver metastasis. A, Liver metastasis of mice injected with 5 X 105 
LvM3b cells over-expressing either a control hairpin, miR-483-5p or miR-551a 
(n>5). Mice were imaged at day 21 after injection and livers extracted for ex vivo
imaging and gross morphological examination. B, Metastatic progression in 
NOD-SCID mice injected with 5 X 105 poorly metastatic LS174T parental cells, 
whose endogenous miR-483-5p or miR-551a activity was inhibited (n>5). Mice 
were imaged at day 28 and euthanized. C, Metastatic progression in mice 
injected with 5 X 105 poorly metastatic SW480 cells, whose endogenous miR-483-
5p or miR-551a was inhibited using LNA targeting miR-483-5p and miR-551a 
(n>5). Mice were imaged at day 28 after injection. p values are based on one-
sided Mann-Whitney test for non-Gaussian distribution.  *p<0.05; **p<0.01; 
***p<0.001. 
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The effects of these microRNAs on metastatic progression were not secondary to 
modulation of intrinsic proliferative capacity since miR-551a inhibition did not 
affect in vitro proliferation, while miR-483-5p inhibition minimally increased
proliferation (10%)—an order of magnitude less than its effect on metastasis (Fig. 
2.6A). Importantly, over-expression of either microRNA did not suppress 
primary tumor growth (Fig. 2.6B). 
Figure 2.6 | Mir-483-5p and miR-551a do not regulate in vitro proliferation and
in vivo primary tumor growth. A, 1x105 SW480 cells whose endogenous miR-
483-5p and miR-551a activity was inhibited were seeded onto a 6-well plate in 
triplicate. Cells numbers were counted after 5 days (n=3). B, 1 X 106 LvM3b cells 
over-expressing a control hairpin, miR-483-5p or miR-551a was injected into the 
subcutaneous flanks of NOD-SCID mice. Tumor volumes were measured over 
time (n=4). Error bars, s.e.m; p values are based on one-sided Student’s t-tests. 
*p<0.05; **p<0.01; ***p<0.001.
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Mir-483-5p and miR-551a suppress colon cancer cell survival in the liver 
microenvironment 
The liver microenvironment is a complex milieu and liver-specific interactions of 
colon cancer cells within the liver might not be easily identified with in vitro
phenotypic assays that do not recapitulate the liver microenvironment. To better 
investigate the mechanism(s) by which miR-483-5p and miR-551a exert their anti-
metastatic effects, an in vitro liver organotypic slice culture system to study
events during liver metastasis was developed. 
The organotypic slice culture system involved the inoculation of colon cancer 
cells labeled with fluorescent dyes or expressing fluorescent proteins into the 
portal circulation of immunodeficient mice through intrasplenic injection, 
allowing for dissemination to the livers (Fig. 2.7A). Following inoculation into 
mice, the animals were euthanized and livers excised. Organotypic slices were 
prepared from the livers and were cultured prior to two-photon microscopy 
imaging of colon cancer cells within the liver slice cultures (Fig. 2.7B). 
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Figure 2.7 | Organotypic slice culture system for in vitro studies of colon
cancer cells interactions within the liver microenvironment. A, Schematic of the 
hepatic organotypic slice culture system for studying events during liver 
colonization by colorectal cancer cells. Colon cancer cells were labeled with cell-
tracker dye and introduced into the livers through intrasplenic injection. The 
livers were then excised and cut into 150um slices and plated onto cell culture 
inserts before imaging by multi-photon microscopy. B, Representative image of 
two colorectal cancer cell populations within the liver microenvironment. Scale 
bar represent 50μm. 
Consistent with prior clinical and experimental studies, which revealed a 
significant selection on cell survival during metastatic colonization (Morikawa et 
al., 1988a; Sugarbaker, 1993), the highly metastatic LvM3b colonizer cells were 
significantly better at persisting in the liver microenvironment than their poorly 
metastatic parental line (Fig. 2.8); consistent with a key role for intrahepatic 
persistence in metastatic progression (Gupta and Massagué, 2006; Talmadge and 
Fidler, 2010). 
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Figure 2.8 | Highly metastatic LvM3b colon cancer cells display enhanced 
intrahepatic persistence. 5 X 105 cells were labeled with cell-tracker green (LS-
Parental) or cell-tracker red (LvM3b) and introduced into the liver. Survival of 
the cells in organotypic cultures was monitored for up to 4 days (n=8). Dye-swap 
experiments were performed to exclude effects of dye bias. Representative 
images at day 0 and day 3 are shown. Scale bar represent 50µm. Error bars, s.e.m; 
all P values are based on one-sided Student’s t-tests. **p<0.01; ***p<0.001. 
To determine whether the enhanced capacity of metastatic cells to persist in the 
hepatic microenvironment could be regulated by miR-483-5p or miR-551a, gain-
of- and loss-of-function studies were performed using the organotypic slice 
culture system. Over-expression of miR-483-5p or miR-551a in highly metastatic 
LS-LvM3b cells suppressed colon cancer persistence in the hepatic 
microenvironment (Fig. 2.9A, B), while inhibition of either microRNA 
significantly enhanced persistence of poorly metastatic SW480 cells (Fig. 2.9 C, D). 
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Figure 2.9 | Mir-483-5p and miR-551a regulate intrahepatic persistence by 
colon cancer cells organotypic slice cultures. A-B, Intrahepatic persistence of of 
LvM3b cells over-expressing miR-483-5p (A) or miR-551a (B) cells in organotypic 
liver slices (n=8). C-D, Intrahepatic persistence of SW480 cells whose endogenous 
miR-483-5p (C) or miR-551a (D) were inhibited by pre-treatment with LNAs 
(n=8). 5 X 105 cells were labeled with cell-tracker green (control LNA) or cell-
tracker red (microRNA targeting LNA) and introduced into the livers prior to 
slice culture. Representative images at day 0 and day 3 are shown. Dye-swap 
experiments were performed to compensate for dye bias. Scale bar represent 
50µm. Error bars, s.e.m; all P values are based on one-sided Student’s t-tests. 
**p<0.01; ***p<0.001. 
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In agreement with the phenotype of hepatic persistence observed via the 
organotypic slice culture assay, colon cancer cells whose endogenous 
microRNAs were inhibited were able to out-compete control cells in the liver as 
early as 24 hours after injection of cells into the portal circulation for hepatic 
metastatic colonization assay (Fig. 2.10). Given that neither of the microRNAs 
regulated proliferation in vitro and in vivo, the ability of the microRNAs to
suppress cancer cell survival during metastatic progression in vivo was
investigated. 
Figure 2.10 | Mir-483-5p and miR-551a regulate early intrahepatic persistence 
by colon cancer cells in vivo. Bioluminescent metastatic signal from mice (n=5)
injected with 5 X 105 SW480 cells whose endogenous miR-483-5p or miR-551a 
activities were inhibited. Images and measurements were taken 24hr after tumor 
cells inoculation. Error bars, s.e.m; all P values are based on one-sided Student’s 
t-tests. ***p<0.001. 
To quantify colon cancer cell death in vivo, a bioluminescent-based luciferin
reporter of caspase-3/7 activity was utilized (Hickson et al., 2010). MicroRNA 
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inhibition significantly reduced in vivo caspase activity in colon cancer cells
during the early phase of hepatic colonization, revealing cancer cells survival to 
be the phenotype suppressed by these microRNAs (Fig. 2.11). Decreased cancer 
cell apoptosis during the early stages of cancer progression has been 
demonstrated to be critical for successful cancer progression (Scabini et al., 2011).  
These in vivo findings provide corroboration and a mechanistic basis for the
organotypic slice culture observations and reveal miR-483 and miR-551a to 
suppress liver metastatic colonization through suppression of metastatic cell 
survival in the liver—a phenotype exhibited by highly metastatic colon cancer 
cells. 
Figure 2.11 | Mir-483-5p and miR-551a regulate colon cancer cell survival 
within the liver. Relative in vivo caspase activities of SW480 cells whose
endogenous miR-483-5p or miR-551a were inhibited and subsequently 
introduced into the liver of immunodeficient mice by intrasplenic injection (n=3). 
Caspase activity was monitored using a caspase-3/7 activated DEVD-luciferin 
and normalized with signal from regular luciferin. Error bars, s.e.m; all P values 
are based on one-sided Student’s t-tests. *p<0.05; **p<0.01. 
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CKB is a common direct target and effector of miR-483-5p and miR-551a 
To delineate the pathways through which miR-483-5p and miR-551a regulate 
colon cancer cell survival in the liver microenvironment, transcriptomic profiling 
was performed to identify mRNA transcripts that were down-regulated upon 
over-expression of each microRNA and that contained 3’-UTR or coding 
sequence elements complementary to the microRNAs. Interestingly, Creatine 
Kinase Brain-type (CKB) was identified as a putative target of both microRNAs 
that could be experimentally validated. As both microRNAs exhibited similar 
phenotypes in the in vitro organotypic slice culture assay, as well as in vivo upon
inoculation into the liver, CKB could be a common target gene and downstream 
effector. Indeed, endogenous miR-483-5p and miR-551a were found to suppress 
CKB protein levels (Fig. 2.12A) in colon cancer cells, and quantitative PCR 
validation also revealed suppression or up-regulation of CKB transcript levels 
upon over-expression or inhibition of the microRNAs, respectively (Fig. 2.12B, C). 
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Figure 2.12 | CKB expression is regulated by miR-483-5p and miR-551a. A, 
Protein levels of CKB in SW480 cells whose endogenous miR-483-5p or miR-551a 
was inhibited with LNAs. B, CKB transcript levels in colorectal cancer cells over-
expressing miR-483-5p or miR-551a (n=3). C, CKB transcript levels in colorectal 
cancer cells whose endogenous miR-483-5p and miR-551a were inhibited by 
LNA (n=3). Error bars, s.e.m; all P values are based on one-sided Student’s t-tests. 
**p<0.01; ***p<0.001. 
In order to confirm that the CKB transcript is a direct target of both microRNAs, 
luciferase-reporter assay was performed in which the coding region and 3’-UTR 
of the CKB transcript were cloned downstream of a luciferase reporter. The 
luciferase reporter assay revealed miR-483-5p to directly target the 3’-UTR (Fig. 
2.13A) and miR-551a to target the coding region of CKB (Fig. 2.13B). Mutagenesis 
of putative microRNA recognition sites abrogated the regulation by the 
microRNAs and confirmed CKB to be direct target of the microRNAs. 
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Figure 2.13 | The CKB transcript is directly targeted by miR-483-5p and miR-
551a. A, B, Luciferase reporter assays of CKB coding sequence and 3’-UTR. A, 
miR-483-5p and B, miR-551a targeted sequences in the 3’-UTR and coding 
sequence of CKB respectively. Inhibition of endogenous miR-483-5p and miR-
551a resulted in increased expression of luciferase reporter. Mutagenesis of 
putative target sites of miR-483-5p and miR-551a on the 3’-UTR and CDS 
respectively abrogated regulation of luciferase reporter by the microRNAs. 
Independent assays were performed as described above at least 3 times. Error 
bars, s.e.m; all P values are based on one-sided Student’s t-tests. **p<0.01; 
***p<0.001. 
Given that CKB is a potential promoter of colon cancer metastasis that is 
regulated by miR-483-5p and miR-551a, gain-of- and loss-of-function 
experiments were performed. Over-expression of CKB in poorly metastatic 
SW480 cells was sufficient to significantly enhance liver metastasis (>3-fold; Fig. 
2.14A), while CKB knockdown in metastatic LS-LvM3b and SW480 cells, through 
the use of two independent shRNA hairpins for each cell-line, robustly 
suppressed liver metastatic colonization (>5 fold, Fig. 2.14B, C). These results 
reveal that CKB is indeed a bona fide promoter of colon cancer liver metastasis.
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Figure 2.14 | CKB is a promoter of colorectal cancer metastasis. A, Liver 
metastasis in mice injected intrasplenically with 5 X 105 poorly metastatic SW480 
cells and CKB over-expressing SW480 cells (n=5). Mice were euthanized at 28 
days after injection and livers excised for ex vivo bioluminescent imaging. B,
Liver metastasis in mice injected with 5 X 105 SW480 cells transduced with two 
independent CKB shRNAs (n=5). Mice were euthanized at 28 days after injection. 
C, Liver metastasis in mice injected intrasplenically with 5 X 105 highly 
aggressive LvM3b expressing a control hairpin or two independent shRNA 
hairpins targeting CKB (n=6). Mice were euthanized 21 days after injection. 
Western-blot was performed to control for CKB expression levels. All P values 
are based on one-sided Mann-Whitney test for non Gaussian distribution. 
*p<0.05; **p<0.01; ***p<0.001.
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In an independent experiment, CKB expression was examined in liver metastases 
that eventually formed from CKB knockdown cells and it was observed that 
recovered tumors were ‘escapers’ with restored CKB expression (Fig. 2.15), 
demonstrating a strong selective pressure for CKB up-regulation in liver 
metastases.  
Figure 2.15 | CKB expression is restored in escaping tumors arising from 
shRNA-mediated CKB-depleted colon cancer cells. CKB protein levels in 
control LvM3b and CKB-knockdown cells, control tumors and escaped CKB 
knockdown tumors from two independent hairpins. Two escaper tumors were 
extracted for each CKB-knockdown cell-line and CKB protein levels were 
examined by western-blot. 
The effects of CKB were also consistent with the phenotypic effects of its 
regulatory microRNAs. CKB over-expression was sufficient to significantly 
enhance the ability of colon cancer cells to persist in the liver microenvironment 
and enhanced their representation in the liver (Fig. 2.16A), while CKB 
knockdown substantially reduced intra-hepatic persistence (Fig. 2.16B). 
Consistent with this, CKB over-expression significantly reduced (Fig. 2.16C), 
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while CKB knockdown significantly increased (Fig. 2.16D), in vivo caspase-3/7
activity in colon cancer cells during the initial phase of hepatic colonization. 
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Figure 2.16 | CKB regulates intrahepatic persistence of colon cancer cells by 
promoting cancer cells survival within the liver microenvironment. A, 
Intrahepatic persistence of control SW480 and CKB over-expressing SW480 cells 
in organotypic liver slices (n=8). B, Organotypic slice cultures of LvM3b cells 
expressing a control hairpin or hairpin targeting CKB (n=8). Representative 
images at day 0 and day 2 are shown. C, Relative in vivo caspase activity of
SW480 cells expressing control or CKB expression vectors in livers of mice 
measured by bioluminescence using a caspase-3 activated DEVD-luciferin 
substrate and normalized to bioluminescence signal from generic luciferin (n=3). 
D, Relative in vivo caspase-3 activity of SW480 cells expressing a control hairpin
or hairpin targeting CKB and introduced into the livers of mice through 
intrasplenic injection. Caspase activity was measured on day 1, 4 and 7 after 
injection (n=3). Error bars, s.e.m; all P values are based on one-sided Student’s t-
tests. *p<0.05; **p<0.01; ***p<0.001. 
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As CKB displayed in vitro and in vivo phenotypes that were consistent with miR-
483-5p and miR-551a, epistasis experiments were performed to confirm CKB as a 
direct downstream effector of both microRNAs. Loss-of-function epistasis 
experiments in which CKB was depleted in cells displaying endogenous miR-
483-5p or miR-551a inhibition prevented the enhanced metastasis effect seen 
with miR-483-5p or miR-551a silencing (Fig. 2.17A). Conversely over-expression 
of CKB was sufficient to rescue the suppressed liver metastatic phenotypes of 
cells over-expressing miR-483-5p or miR-551a (Fig. 2.17B). 
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Figure 2.17 | CKB is a direct downstream effector of miR-483-5p and miR-551a. 
A, Liver metastasis in mice injected with 5 X 105 SW480 cells whose endogenous 
miR-483-5p or miR-551a was inhibited by LNA, with and without CKB 
knockdown (n=5). Mice were euthanized after 28 days and livers were excised 
for ex vivo bioluminescence imaging. B, Metastatic progression in mice injected
with 5 X 105 LvM3b cells over-expressing miR-483-5p or miR-551a, with and 
without CKB over-expression (n=5). P values are based on one-sided Mann-
Whitney test for non-Gaussian distribution. *p<0.05; **p<0.01. 
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The results of the above mutational, gain-of-, loss-of-function and epistasis 
analyses confirmed CKB to be a direct downstream effector of miR-483-5p and 
miR-551a and revealed CKB to be a promoter of colon cancer survival during 
metastatic colonization in the hepatic microenvironment. The restoration of CKB 
levels in tumors that ‘escaped’ from CKB depletion by RNAi also highlighted a 
strong selective pressure for CKB expression in liver metastases. 
Summary of Chapter II 
Chapter II describes two complementary approaches used to identify 
microRNAs that suppressed colon cancer metastasis. The first approach 
employed a lentiviral microRNA library screen in two independent cell-lines, 
SW620 and WiDr, to identify microRNAs that when over-expressed, suppressed 
liver colonization. A third independent cell-line, LS174T, was subjected to in vivo 
selection to select for sub-lines with enhanced metastatic colonization capacity of 
the liver. Two microRNAs, miR-483-5p and miR-551a were identified through 
both approaches. In vivo and in vitro phenotypic assays revealed both
microRNAs to suppress liver metastasis by colon cancer cells through 
suppression of colon cancer cells survival in the liver microenvironment. 
Transcriptomic analysis followed by gain-of- and loss-of-function validation 
experiments, as well as luciferase reporter assays identified CKB as direct target 
of miR-483-5p and miR-551a. Functional CKB over-expression and knockdown 
experiments using in vivo metastasis assays and in vitro liver organotypic slice
culture assays demonstrated CKB to regulate colon cancer metastasis and cell 
survival in the liver, consistent with its regulatory microRNAs. CKB was further 
! 51!
confirmed to be a direct downstream effector of miR-483-5p and miR-551a 
through in vivo epistasis experiments. The following chapter shall present efforts
to mechanistically dissect the pathways regulated by the microRNAs and CKB 
that mediate colon cancer metastasis to the liver (Chapter III). 
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Chapter III: Mechanistic Studies of the Creatine Kinase Axis During 
Colorectal Cancer Metastasis to the Liver 
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CKB is a member of the creatine kinase family of metabolic kinases that are 
known to regulate the reservoir of rapidly mobilized high-energy phosphates in 
tissues with high energetic demands such as the brain, muscles and heart by 
catalyzing the transfer of a high-energy phosphate group from ATP to the 
metabolite creatine, yielding phosphocreatine (Wallimann et al., 1992; Wyss and 
Kaddurah-Daouk, 2000). As CKB was demonstrated to be regulator of colon 
cancer metastasis in Chapter II, it is possible that the metabolic reaction catalyzed 
by CKB is also relevant to colon cancer metastasis. This chapter describes efforts 
to delineate the pathways regulated by CKB in colon cancer cells in relation to 
the physiological context of the liver microenvironment. 
CKB modulates cellular energetics of colon cancer cells 
The maintenance of intracellular ATP levels is critical for cell survival under 
energetic stress. In normal tissues, cells with potentially high energetic demands 
maintain high levels of phosphocreatine stores in order to buffer against low 
ATP states, since phosphocreatine’s high-energy phosphate can be transferred to 
ADP to generate ATP (Wallimann et al., 1992). Consistent with the role of CKB in 
modulating phosphocreatine and ATP levels within cells, over-expression and 
knockdown of CKB in colon cancer cells increased and decreased, respectively, 
intracellular phosphocreatine levels (Fig. 3.1A) and CKB depletion resulted in 
decreased ATP levels that could be rescued by phosphocreatine supplementation 
(Fig. 3.1B), consistent with what was previously reported for creatine kinase 
expressing tissues (Li et al., 2012; Prabhakar et al., 2003). 
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Figure 3.1 | CKB regulates intracellular levels of high-energy phosphate 
metabolites. A, Relative intracellular phosphocreatine levels in colorectal cancer 
cells over-expressing CKB or depleted for CKB using a bioluminescent assay 
(n=5). Bioluminescent signals from experimental groups are directly proportional 
to intracellular phosphocreatine levels and normalized to signal from control 
cells. B, Relative intracellular ATP levels in colorectal cancer cells depleted for 
CKB, with and without exogenous 10mM phosphocreatine supplementation 
(n=5). Error bars, s.e.m; P values are based on one-sided Student’s t-tests. *p<0.05; 
***p<0.001. 
As miR-483-5p and miR-551a are regulators of CKB expression, modulation of 
either microRNAs also modulated intracellular phosphocreatine (Fig. 3.2A, B) 
and ATP levels (Fig. 3.2C, D). These findings demonstrated regulation of high-
energy metabolites by CKB as a potential avenue through which CKB can 
promote liver metastasis. 
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Figure 3.2 | Mir-483-5p and miR-551a regulate intracellular levels of high-
energy phosphate metabolites. A, Relative intracellular phosphocreatine levels 
in LvM3b cells over-expressing miR-483-5p and miR-551a (n=3). B, Relative 
intracellular phosphocreatine levels in SW480 cells in which endogenous miR-
483-5p and miR-551a was inhibited (n=3). C, Relative intracellular ATP levels in 
LvM3b cells over-expressing miR-483-5p and miR-551a (n=3). D, Relative 
intracellular ATP levels in SW480 cells in which endogenous miR-483-5p and 
miR-551a was inhibited (n=3). Error bars, s.e.m; all P values are based on one-
sided Student’s t-tests. *p<0.05; ***p<0.001. 
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CKB mediates colon cancer cell survival in the hypoxic liver 
microenvironment 
In the previous chapter, it was showed that CKB promotes colon cancer cell 
persistence and survival at an early phase after dissemination to the liver 
microenvironment. Newly disseminated colon cancer cells that arrive in the liver 
could thus encounter a physiological context that can result in low ATP levels 
unless buffered by a higher intracellular phosphocreatine reservoir as a result of 
high CKB expression.  
The liver microenvironment is known to contain hypoxic regions (Arteel et al., 
1995), with metabolically active hepatocytes at the periportal region displaying 
high rates of oxygen consumption and hepatocytes at the perivenous region 
actively undergoing glycolysis (Jungermann and Kietzmann, 1996, 2000). 
Additionally, colon cancer cells metastasize to the liver via the portal circulation, 
which is relatively hypoxemic (Weiss et al., 1986). It is possible that colon cancer 
cells experience acute hypoxia and intense competition for glycolytic substrates 
during initial dissemination to the liver and could be poorly adapted to the liver 
microenvironment prior to HIF activated responses (Semenza, 2011). To 
determine if colon cancer cells are disseminated to hypoxic regions of the mouse 
liver, a HIF-1 alpha transcriptional luciferase reporter (HRE-Luc) was used as an 
in vivo sensor and reporter of cellular hypoxia (Fig. 3.3A). Subsequent to colon
cancer cells inoculation into the liver, it was observed that colon cancer cells 
indeed experience hypoxia early after hepatic dissemination (Fig. 3.3B). As an 
independent in vivo reporter for hypoxia that is not dependent on HIF1A
activation, a luciferase reporter fused to an oxygen degradative domain (ODD-
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Luc) was used (Fig.3.3C) (Safran et al., 2006). Colon cancer cells that 
disseminated to the liver expressed ODD-Luc (Fig. 3.3D), independently 
indicating that low oxygen levels were indeed a physiological stress present in 
the liver microenvironment. 
Figure 3.3 | Incipient colorectal cancer cells experience hypoxia within the 
liver microenvironment during metastasis. A, Bioluminescent imaging of 
SW480 cells expressing an HRE-luciferase reporter with and without 24hr CoCl2
treatment. B, Bioluminescence imaging of mice (n=5) injected with 5 X 105 SW480 
cells expressing the HRE-luciferase reporter. C, Bioluminescent imaging of 
SW480 cells expressing the ODD-luciferase reporter cultured in atmospheric 
conditions or 1% O2. D, Bioluminescent imaging of mice injected with 5 X 105 
SW480 cells expressing ODD-luciferase reporter. 
Hypoxia can result in cellular energetic stress, ATP depletion and subsequently 
apoptotic cell death (Steinbach et al., 2003). Using the in vivo HRE-Luc reporter
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for hypoxia and the caspase-activated luciferin substrate as system for 
investigating colon cancer cell death under hypoxia in vivo, it was observed that
CKB depletion increased caspase-mediated cell death in HRE-Luc expressing 
cells experiencing hypoxia in vivo (Fig. 3.4A).  Conversely, inhibition of either
miR-483-5p or miR-551a protected colon cancer cells experiencing hypoxia in vivo
(Fig. 3.4B). These results indicated CKB to be a pro-survival metabolic kinase in 
colon cancer cells during hypoxia. 
Figure 3.4 | CKB promotes colon cancer cells survival within the hypoxic liver 
microenvironment during incipient metastasis. A, In vivo caspase activity of
control SW480 cells and CKB knockdown SW480 cells experiencing hypoxia 
within the livers of mice (n=3). Cells expressed an HRE-driven luciferase reporter 
and caspase-3 activity was measured using DEVD-luciferin and normalized to 
using regular luciferin. B, In vivo caspase activity of hypoxic SW480 cells with
inhibition of miR-483-5p or miR-551a in the livers of mice (n=3). Imaging was 
performed on day 1, 4, and 7 after injection. Error bars, s.e.m; all P values are 
based on one-sided Student’s t-tests. *p<0.05; **p<0.01, ***p<0.001. 
Consistent with a role for CKB and its enzymatic product, phosphocreatine, in 
promoting tissue integrity and cell survival during hypoxia or ischemia (Miller et 
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al., 1993; Prabhakar et al., 2003; Sharov et al., 1987), cells depleted of CKB 
through RNAi displayed reduced survival while experiencing hypoxia in vitro—
an effect that was abrogated upon phosphocreatine supplementation (Fig. 3.5).  
Figure 3.5 | Phosphocreatine is protective of colon cancer cells experiencing 
hypoxia. Survival of colorectal cancer cells in hypoxia in vitro with and without
CKB knockdown, and 10mM phosphocreatine supplementation (n=3). Cells were 
culture in 1% O2 for 96hrs. Error bars, s.e.m; all P values are based on one-sided 
Student’s t-tests. **p<0.01; ***p<0.001. 
In agreement with the in vitro findings, pre-incubation of colon cancer cells
depleted of CKB with phosphocreatine enhanced their ability to metastasize to 
the liver (Fig. 3.6A) while depletion of intracellular phosphocreatine by pre-
incubating colon cancer cells with cyclocreatine, an inhibitor of CKB, suppressed 
liver metastasis (Lillie et al., 1993) (Fig. 3.6B). The above findings suggested that 
hepatic hypoxia poses a survival barrier for colon cancer cells during early 
metastatic colonization and cells endure this phase through the generation of 
ATP from phosphocreatine reserves. The ability of phosphocreatine pre-loading 
to enhance metastasis in vivo supports the importance of the acute initial hypoxic
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barrier and energetic demands in shaping metastatic colonization by cancer cells 
as they enter the liver microenvironment. The findings that exogenous 
phosphocreatine can be protective for colorectal cancer cells during hypoxia 
were in agreement with earlier studies demonstrating that exogenous 
phosphocreatine can be protective against hypoxic, ischemic and other energetic 
insults in neurons and myocardium, with increased phosphocreatine uptake 
observed in ischemic myocardium (Brustovetsky et al., 2001; Li et al., 2012; 
Sharov et al., 1987). 
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Figure 3.6 | Intracellular phosphocreatine contributes to colon cancer cell 
metastasis to the liver.  A, Liver metastasis by CKB depleted LvM3b cells pre-
incubated overnight with 10mM phosphocreatine. 5 X 105 cells were then 
inoculated into the liver of mice through intrasplenic injection. B, Liver 
metastasis in mice injected with 5 X 105 LvM3b cells with and without pre-
treatment with 10mM cyclocreatine for 48hrs prior to injection. P values are 
based on Mann-Whitney test for non-Gaussian distribution. **p<0.01; ***p<0.001. 
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Secreted CKB catalyzes an extracellular reaction that promotes colon cancer 
progression 
CKB was shown to regulate the cellular energetics of colon cancer cells and 
promoted cancer cell survival during in vivo and in vitro hypoxia through
phosphocreatine generation. While further considering CKB’s role in the setting 
of the hypoxia hepatic microenvironment, a conundrum arose: how can colon 
cancer cells arriving and residing in a hypoxic hepatic microenvironment 
generate and replenish phosphocreatine if they are depleted of ATP, especially 
during the acute phase, prior to any hypoxia-response (Bertout et al., 2008; 
Semenza, 2013; Wheaton and Chandel, 2011)? An exogenous source of ATP 
would therefore be required for supplemental phosphocreatine generation. 
Earlier clinical studies have described the detection of CKB proteins and CKB 
activity in the sera of patients with various forms of malignancies and 
physiological insults (Huddleston et al., 2005; Rubery et al., 1982; Wyss and 
Kaddurah-Daouk, 2000). The presence of extracellular ATP in the 
microenvironment of macro-metastases was also reported (Pellegatti et al., 2008; 
Stagg and Smyth, 2010). Interestingly, the liver is the main synthetic organ for 
creatine synthesis in the body, responsible for releasing creatine into the 
circulation for distribution to other tissues. Given that the substrates and enzyme 
required for phosphocreatine generation were reported in earlier literature, a 
hypothesis was developed that colon cancer cells may release CKB into the 
extracellular space, which can then convert extracellular ATP and liver-produced 
creatine into phosphocreatine. This exogenous phosphocreatine can then taken 
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up by cancer cells, thereby exerting a protective effect on hypoxic colon cancer 
cells prior to their adaption to the hypoxic liver microenvironment.  
To investigate this hypothesis, the presence of extracellular ATP and CKB has to 
be confirmed. Cell culture supernatant from metastatic LvM3b cells and LvM3b 
cells depleted of CKB through RNAi were collected and examine for CKB protein 
levels. Extracellular CKB were released from LvM3b cells, but not CKB-depleted 
LvM3b cells (Fig. 3.7). 
Figure 3.7 | Colon cancer cells release CKB extracellularly. Extracellular and 
intracellular CKB protein levels in control and LvM3b cells depleted of CKB 
through RNAi. Supernatant was harvested by culturing LvM3b cells overnight in 
serum-free media. Cells viability was confirmed to be above 99% using trypan 
blue exclusion assay. Supernatant was concentrated 20-fold using column 
centrifugation and 40μL was used for western-blot. 
In order to determine if extracellular CKB was released from live or dying cells, a 
FLAG-tagged CKB expression construct was generated. The FLAG-epitope is 
! 64
attached to CKB through a peptide linker containing a caspase-3/7 recognition 
DEVD motif. Caspase activation in apoptotic cells would result in caspase 
recognition and cleavage of the DEVD motif between the FLAG-epitope tag and 
CKB, causing loss of the FLAG-epitope from the expression CKB (Fig. 3.8A). 
Supernatant from colon cancer cells expressing this FLAG-tagged CKB indicated 
that the FLAG-epitope was not lost, demonstrating that extracellular CKB to be 
released by primarily live cells (Fig. 3.8B). Interestingly, release of extracellular 
CKB was not inhibited by brefeldin A or dimethyl amiloride (DMA) treatment 
(Fig. 3.8C) raising the possibility that CKB release was not mediated by golgi-
related secretory pathways or exosomes respectively. 
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Figure 3.8 | CKB is released by live cells. A, FLAG-tagged CKB with a caspase 
3/7 recognition site linker. The FLAG-DEVD-CKB has a FLAG-tag linked to the 
N-terminal of CKB by a linker containing a caspase 3/7 recognition motif 
(DEVD-amino sequence). Caspase activation by apoptotic cells will result in 
cleavage of linker and release of FLAG-tag. B, Western-blot of FLAG-DEVD-CKB 
over-expressing cells demonstrates release of CKB by live cells into the 
extracellular space. FLAG-tag was not cleaved upon CKB release into the 
extracellular space. C, Western-blot of FLAG-tagged CKB in supernatant of cells 
treated with Brefeldin A or Dimethyl-amiloride. 
As generation of extracellular phosphocreatine requires exogenous ATP, the 
presence of extracellular ATP in the microenvironment of newly disseminated 
colon cancer cells or incipient micro-metastases was investigated using a plasma 
membrane-anchored luciferase reporter for detecting extracellular ATP (pME-
Luciferase)(Pellegatti et al., 2005). Extracellular ATP was confirmed to be present 
in the microenvironment of disseminated colon cancer cells (Fig. 3.9). 
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Figure 3.9 | Extracellular ATP is present in the extracellular microenvironment 
of disseminated colon cancer cells within the liver. 5 x 105 SW480 cells 
expressing pME-Luc were inoculated into the liver of mice through intrasplenic 
injection. The presence of extracellular ATP was detected by bioluminescent 
imaging. 
Given the presence of extracellular ATP and CKB, if the pro-metastatic effects of 
CKB resulted from utilization of extracellular ATP as a substrate for 
phosphocreatine generation by CKB, then depleting extracellular ATP should 
suppress the pro-metastatic activity of CKB. Indeed, expressing CD39, a plasma 
membrane anchored ATP hydrolase in SW480 cells (Kaczmarek et al., 1996), 
significantly precluded the ability of CKB over-expression to promote metastasis 
without affecting CKB levels (Fig. 3.10). 
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Figure 3.10 | Depletion of extracellular ATP attenuates CKB mediated liver 
metastasis by colon cancer cells. 5 x 105 SW480 control cells, or cells over-
expressing CKB alone, or with concomitant over-expression of CD39 was 
introduced into livers of mice through intrasplenic injection (n=5). Metastatic 
burden was monitored by bioluminescent imaging and mice euthanized at day 
28. Liver was excised for ex vivo bioluminescent imaging and gross examination.
Western-blot was performed to determine CD39 over-expression. P values are 
based on one-sided Mann-Whitney test for non-Gaussian distribution. *p<0.05; 
**p<0.01. 
Consistent with CKB consumption of extracellular ATP, cells over-expressing 
CKB or cells whose endogenous miR-483-5p or miR-551a were inhibited 
displayed significantly lower extracellular ATP levels in vivo relative to the
control cells (Fig. 3.11A, C). Conversely, the microenvironment surrounding CKB 
knockdown cells displayed higher extracellular ATP levels (Fig. 3.11B). 
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Figure 3.11 | Extracellular ATP levels of incipient metastases is modulated by 
CKB expression. A, Relative extracellular ATP levels in CKB over-expressing 
cells. Control and CKB over-expressing pME-Luc SW480 cells were injected into 
mice. Mice were imaged one hour after injection to detect the presence of 
extracellular ATP (n=5). Bioluminescent signal is directly proportional to levels 
of extracellular ATP. B, Control and CKB depleted pME-Luc SW480 cells were 
injected into mice (n=5). C, Relative extracellular ATP levels in 
microenvironment of SW480 cells whose endogenous miR-483-5p and miR-551a 
were inhibited. 5 X 105 SW480 cells expressing pME-Luc and whose endogenous 
miRNAs were inhibited were introduced into the portal circulation through 
intrasplenic injection and bioluminescent imaging performed (n=5). Error bars, 
s.e.m; all P values are based on one-sided Student’s t-tests. *p<0.05; **p<0.01. 
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If extracellular CKB catalysis can enhance metastasis, presence of the product of 
CKB-mediated catalysis, phosphocreatine, in the extracellular space should 
partially rescue the effect of CKB loss-of-function. In order to investigate this 
possibility, mini osmotic pumps that continuously released phosphocreatine 
were implanted into the peritoneal cavities of immunodeficient mice. Exogenous 
phosphocreatine released from the pump and draining into the portal circulation 
was able to significantly enhance metastasis (>10 fold) by CKB-depleted cells in 
vivo (Fig. 3.12).
Figure 3.12 | Exogenous phosphocreatine contributes to colon cancer 
metastasis to the liver. Liver metastasis by CKB-depleted LvM3b cells in mice 
implanted with an osmotic pump releasing phosphocreatine into the portal 
circulation (n=8). P values are based Mann-Whitney test for non-Gaussian 
distribution. **p<0.01. 
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To further confirm that extracellular CKB can promote the survival of colon 
cancer cells depleted of CKB during hypoxia, a boyden chamber co-culture 
system was used (Fig. 3.13A). CKB over-expressing cells were able to compensate 
for the survival of CKB depleted cells across the trans-well, while addition of a 
CKB-activity neutralizing antibody abrogated this effect (Fig. 3.13B). 
Figure 3.13 | Extracellular CKB enhances colon cancer cell survival in hypoxia 
in vitro. A, 5 X 104 CKB-knockdown cells were cultured on the bottom of 24-well
plates, while control or CKB-over-expressing cells were plated onto boyden 
chambers above CKB-knockdown cells with pores for exchange of metabolites 
and proteins. Cells at the bottom of the well were counted after 4 days in hypoxia. 
B, Relative survival of CKB-knockdown cells in 1% oxygen when co-cultured 
with control, CKB-over-expressing cells or with CKB-over-expressing cells in the 
presence of a neutralizing antibody (n=4). Error bars, s.e.m; all P values are based 
on one-sided Student’s t-tests. **p<0.01; ***p<0.001. 
To further extend these findings to an in vivo system, colon cancer cells depleted
of intracellular CKB but expressing a secreted form of CKB wherein CKB is fused 
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to the IgK secretory signal sequence was generated. Over-expression of secreted 
CKB was sufficient to enhance colon cancer metastasis in CKB depleted colon 
cancer cells (Fig. 3.14). 
Figure 3.14 | Extracellular CKB promotes liver metastasis by colon cancer cells. 
Liver metastasis by SW480 CKB-knockdown cells over-expressing a secreted 
form of CKB. 5 x 105 cells were introduced into mice through intrasplenic 
injection. Liver metastasis were monitored by bioluminescent imaging and mice 
were euthanized after 28 days, liver excised for ex vivo bioluminescent imaging
and gross morphology. P values are based on one-sided Mann-Whitney test for 
non-Gaussian distribution. **p<0.01. 
Further evidence for the role of extracellular CKB during metastatic progression 
was observed from serum of mice injected with CKB knockdown cells—mice 
with tumors invariably exhibited increased serum CKB levels (Fig. 3.15), in 
agreement with earlier clinical observations of patients with advanced 
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malignancies having higher serum CKB activity or protein levels (Huddleston et 
al., 2005; Rubery et al., 1982).  
Figure 3.15 | Extracellular CKB is present in the circulation of mice with 
metastatic burden. CKB levels in serum of mice injected with CKB-knockdown 
LvM3b cells with and without metastatic burden as a result of escaped tumors. 
Blood was obtained from mice via cardiac puncture after anesthesia. After 
incubation at room temperature for 30min, serum was obtained after 
centrifugation at 200g for 10min. Serum was diluted 1:10 and 10ul used for 
western-blot. 
The SLC6a8 membrane channel is an effector in the CKB axis 
The present findings implicated CKB and exogenous creatine/phosphocreatine 
metabolism in colon cancer metastasis. It is possible that other components of 
creatine/phosphocreatine metabolism could also mediate colon cancer metastatic 
progression. Depletion of guanidinoacetate methyltransferase (GAMT), the 
enzyme for the final step of creatine synthesis (da Silva et al., 2009), in colon 
cancer cells did not affect metastasis (Fig. 3.16), consistent with a model wherein 
an extracellular source (the liver is the primary site of creatine biosynthesis) of, 
rather than intracellular creatine drives colon cancer metastasis. 
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Figure 3.16 | Colon cancer cells-derived creatine does not contribute to liver 
metastasis. 5 X 105 LvM3b control cells or cells depleted of GAMT by RNAi were 
introduced into immunodeficient mice and liver metastases were monitored by 
bioluminescence (n=5). Mice were euthanized at day 21 and liver excised out for 
ex vivo bioluminescent imaging and gross morphology examination. P values are
based on one-sided Mann-Whitney test for non-Gaussian distribution. 
In agreement with the above observations, SLC6a8, a transporter of creatine 
compounds (Salomons et al., 2001), was found to modulate phosphocreatine 
levels in colon cancer cells; SLC6a8 knockdown reduced intracellular 
phosphocreatine and ATP levels (Fig. 3.17A, B). 
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Figure 3.17 | SLC6a8 regulates intracellular levels of phosphocreatine and 
ATP. A, Relative intracellular phosphocreatine levels in LvM3b cells expressing a 
shRNA targeting SLC6a8 (n=4). B, Relative intracellular ATP levels in LvM3b 
cells expressing a shRNA targeting SLC6a8 (n=4). Error bars, s.e.m; all P values 
are based on one-sided Student’s t-tests. ***p<0.001. 
As depletion of phosphocreatine and ATP in colon cancer cells from CKB 
knockdown or inhibition was able to suppress metastasis, depletion of SLC6a8 
should also suppress colon cancer metastasis. Indeed, LvM3b and SW480 colon 
cancer cells depleted of SLC6a8 displayed substantially reduced (10 to 100-fold) 
metastatic activity (Fig. 3.18A, B). Metastatic tumors that eventually grew out 
from SLC6a8 knockdown cells were ‘escapers’ and displayed restored SLC6a8 
expression (Fig. 3.18C). 
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Figure 3.18 | SLC6a8 is a regulator of colon cancer metastasis to the liver. A, 
Liver metastasis by SW480 cells expressing two independent short hairpins 
targeting SLC6a8 (n=5). 5 X 105 cells were injected into immunodeficient mice. 
Metastatic progression was monitored using bioluminescence imaging. Mice 
were euthanized at day 28 and livers excised. B, Liver metastasis by LvM3b cells 
expressing two independent short hairpins targeting SLC6a8 (n=8). 5 X 105 cells 
were injected into immunodeficient mice. Metastatic progression was monitored 
using bioluminescence imaging. Mice were euthanized at day 21 and livers 
excised.  C, CKB levels in SLC6a8-knockdown LvM3b cells and from escaped 
tumors growing out from SLC6a8-knockdown cells injected intro mice. P values 
are based on one-sided Mann-Whitney test for non-Gaussian distribution. 
**p<0.01; ***p<0.001. 
Importantly, SLC6a8 knockdown, which depleted cellular uptake of extracellular 
phosphocreatine, also abrogated the effect of CKB over-expression on colorectal 
cancer metastasis (Fig. 3.19), revealing extracellular phosphocreatine uptake to be 
downstream of CKB catalysis. 
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Figure 3.19 | SLC6a8 is required for CKB mediated colon cancer metastasis to 
the liver. Liver metastasis by SW480 cells over-expressing CKB with and without 
SLC6a8 depletion. 5 X 105 cells were injected into immunodeficient mice (n>4) 
and metastatic burden monitored by bioluminescent imaging. Mice were 
euthanized at day 28 and liver excised for gross morphological examination. 
Additionally, depleting SLC6a8 in CKB knockdown cells abrogated the 
protective effect of phosphocreatine during hypoxic stress in vitro (Fig. 3.20A),
while exogenously added phosphocreatine was not able to promote liver 
metastasis by SLC6a8 knockdown cells (Fig. 3.20B). These findings revealed 
SLC6a8 to be downstream of CKB and phosphocreatine in mediating their 
metastasis-promoting effects. 
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Figure 3.20 | Depletion of SLC6a8 abrogated the effects of exogenously added 
phosphocreatine. A, In vitro survival of LvM3b cells depleted of CKB, SLC6a8
with and without phosphocreatine supplementation in hypoxia (n=3). B, Liver 
metastasis in mice injected with 5 X 105 LvM3b cells transduced with shRNA 
targeting SLC6a8 in mice implanted with osmotic pumps delivering 
phosphocreatine into the portal circulation. Metastatic progression was 
monitored by bioluminescent imaging and mice were euthanized 28 days after 
injection. Error bars, s.e.m; all P values are based on one-sided Student’s t-tests or 
when appropriate, one-sided Mann-Whitney test for non-Gaussian distribution. 
**p<0.01. 
Summary of Chapter III 
In Chapter III, efforts to delineate the mechanisms mediated by CKB in 
promoting colon cancer cell survival in the hepatic microenvironment were 
described. It was observed that disseminated colon cancer cells experience 
hypoxia upon arrival into the liver. CKB enhanced survival of colon cancer cells 
under hypoxia in vivo and in vitro through regulation of intra- and extracellular
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phosphocreatine and ATP levels. Maintenance of intracellular phosphocreatine 
and ATP levels was shown to be necessary for cancer cell survival under hypoxic 
stress during liver metastasis as depletion of these high-energy metabolites 
prevented liver metastasis by colon cancer cells. In addition to CKB’s role in 
modulating intracellular ATP and phosphocreatine levels, CKB can be secreted 
by colon cancer into the extracellular milieu where it converts exogenous ATP 
and creatine into phosphocreatine that can be imported into cancer cells as an 
additional source of ATP to fuel metastatic survival and progression. 
Additional components of the creatine/phosphocreatine pathway were also 
examined for their role in colon cancer metastasis. Exogenous, liver-derived 
creatine was found to be important for cancer metastasis as endogenous GAMT 
was not required for successful liver colonization by colon cancer cells. SLC6a8, a 
membrane transporter that is involved in the transport of creatine compounds 
was required for colon cancer metastasis downstream of CKB, further indicating 
the contribution of exogenous phosphocreatine to successful metastatic 
colonization in coordination with extracellular CKB. In light of the critical roles 
played by various components of the CKB metabolic axis, Chapter IV will 
examine the translational viability of these scientific observations. The 
therapeutic potential of the above pathway will also be investigated through 
proof-of-principle therapeutic intervention. 
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Clinical Relevance and Therapeutic Targeting of the Creatine Kinase Axis 
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With the identification of a miR-483-5p and miR-551a regulated, CKB-mediated 
pathway (Chapter II and Chapter III) that is critical for colon cancer metastasis to 
the liver, it is important to examine the relevance of this pathway to human 
patients. Should this pathway be pertinent to colorectal cancer patients, it would 
be of clinical interest to see if therapeutic perturbation of this pathway could 
prevent colon cancer metastasis to the liver. This chapter describes the 
interrogation of multiple archival patient samples for expression levels of the 
microRNAs as well as CKB and SLC6a8 and their relation to metastatic 
progression. The potential for therapeutic intervention in this pathway in 
preventing metastasis is also investigated in this chapter. Finally the relevance of 
this pathway to liver metastasis by another gastrointestinal cancer, pancreatic 
cancer was investigated. 
Mir-483-5p and miR-551a expression are decreased in liver metastases relative 
to primary tumors 
To determine if miR-483-5p and miR-551a expression levels were suppressed in 
liver metastases of colon cancer patients, archival RNA samples from a set of 66 
surgically resected primary colon cancer tumors and liver metastases were 
obtained from Memorial Sloan-Kettering Cancer Center (MSKCC). Quantitative 
real-time PCR was performed to examine the relative levels of these microRNAs 
in these patient samples. Consistent with a metastasis-suppressive role for these 
microRNAs during cancer progression, miR-483-5p and miR-551a both 
independently displayed significantly reduced expression levels in human liver 
metastases relative to primary colon cancers (Fig. 4.1A, B). 
! 81
Figure 4.1 | Expression levels of mir-483-5p and miR-551a are decreased in 
liver metastases compared to primary tumors from patients. A, MiR-483-5p and 
B, miR-551a levels in 36 primary colorectal adenocarcinomas and 30 liver 
metastases were quantified by quantitative real-time PCR. Error bars, s.e.m; all P 
values are based on one-sided Student’s t-tests. *p<0.05; **p<0.01. 
CKB and SLC6a8 display increased expression in liver metastases relative to 
primary tumors 
With the experimental observations that CKB and SLC6a8 were important 
effectors for liver metastasis and the strong selective pressure for CKB and 
SLC6a8 in escaped liver nodules, the expression levels of CKB and SLC6a8 were 
examined in multiple sets of archival samples to determine if CKB and SLC6a8 
expression were selected for in liver metastases of patients. CKB and SLC6a8 
transcript levels in the above-described archival RNA samples from MSKCC 
were examined by quantitative real-time PCR. Both CKB and SLC6a8 transcripts 
were significantly increased in liver metastases relative to primary tumors (Fig. 
! 82
4.2A, B), supporting a model in which CKB and SLC6a8 are selected for during 
colon cancer progression. 
Figure 4.2 | Expression levels of CKB and SLC6a8 are increased in liver 
metastases compared to primary tumors from patients. A, CKB and B, SLC6a8 
levels in 36 primary colorectal adenocarcinomas and 30 liver metastases were 
quantified by quantitative real-time PCR. Error bars, s.e.m; all P values are based 
on one-sided Student’s t-tests. *p<0.05. 
Given that both miR-483-5p and miR-551a were negative regulators of CKB, the 
correlation between the expression levels of miR-483-5p and miR-551a and CKB 
in patients that had low expression of these microRNAs was examined. Indeed, 
there was significant negative correlation between CKB expression levels and 
that of the microRNAs (Fig. 4.3A). Additionally, in nine patient-derived colon 
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cancer cell-lines, the expression levels of the microRNAs and CKB were 
significantly negatively correlated as well (Fig. 4.3B). 
Figure 4.3 | Expression levels of CKB and the microRNAs are negatively 
correlated in patient samples. A, MicroRNA and CKB expression levels in 
archival RNA samples from MSKCC. B, Expression levels of microRNAs and 
CKB in patient-derived primary colon cancer cell-lines. 
As an independent validation set, a tissue microarray was constructed from a 
collection of primary colorectal cancer tumors and liver metastases that were 
surgically resected from patients at Weill-Cornell Medical Center (WCMC) and 
New York Presbyterian Hospital (NYPH). The tissue microarray was 
immunohistochemically stained for CKB and SLC6a8 expression. Both CKB and 
SLC6a8 protein expression levels were found to be elevated in liver metastases 
relative to primary tumors of patients (Fig. 4.4A, B).  
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Figure 4.4 | Protein expression of CKB and SLC6a8 are increased in liver 
metastases of an independent cohort of patients compared to primary tumors. 
A, Immunohistochemical staining of CKB on a tissue microarray constructed 
from liver metastases and primary tumors of patients from New York 
Presbyterian Hospital. B, Immunohisochemical staining of SLC6a8 in liver 
metastases and primary tumors of patients. P values are based on one-sided 
Mann-Whitney test for non-Gaussian distribution. *p<0.05; **p<0.01. 
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In addition to the clinical samples obtained from MSKCC, WCMC and NYPH, a 
publicly available gene expression dataset was also analyzed for expression 
levels of CKB and SLC6a8 (Sheffer et al., 2009). This additional dataset 
demonstrated higher levels of CKB and SLC6a8 in liver metastases of patients 
compared to primary tumors as well (Fig. 4.5A, B). 
Figure 4.5 | Expression levels of CKB and SLC6a8 in primary tumors and liver 
metastases obtained from a publicly available microarray dataset. A, B, CKB 
and SLC6a8 expression from a public microarray dataset (GSE41258) comparing 
primary tumors and liver metastases (N=233). P values are based on one-sided 
Mann-Whitney’s test. *p<0.05; ***p<0.001. 
The above findings are consistent with the present experimental findings, and 
suggest the pathophysiological basis for, previous studies describing elevated 
expression levels of CKB in advanced stage cancers (Wallimann and Hemmer, 
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1994) and reveal significant association between the components of miR-483-5p 
and miR-551a regulated multi-microRNA network and colon cancer progression. 
Therapeutic delivery of miR-483-5p and miR-551a suppress colon cancer 
metastasis 
With the findings that deregulation of the expression levels of microRNAs, CKB 
and SLC6a8 is relevant to colon cancer patients; the potential for therapeutic 
intervention targeting this multi-microRNA regulatory network was investigated. 
Adeno-associated virus delivery of microRNAs was previously described to 
suppress hepatic carcinogenesis in a mouse model of hepatocellular carcinoma 
(Kota et al., 2009). It may be possible that adeno-associated virus could infect 
colon cancer cells and suppress colon cancer metastasis to the liver in vivo. As a
first step towards determining if adeno-associated viruses are viable vectors for 
delivery of microRNAs into colon cancer cells, the ability of adeno-associated 
virus to transduce colon cancer cells in vitro was examined. Adeno-associated
viruses were able to transduce colon cancer cells even at low multiplicity of 
infection in vitro (Fig. 4.6A). Injection of mice bearing macroscopic hepatic
metastases with adeno-associated virus revealed that adeno-associated virus was 
able to infect colon cancer metastases in vivo as well and could therefore be a
suitable microRNA delivery vector (Fig. 4.6B). 
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Figure 4.6 | Adeno-associated viral vectors are able to infect colon cancer cells 
in vitro and in vivo. A, PCR amplification of adeno-associated viral DNA
extracted from SW480 cells directly transduced with AAV in vitro at indicated
multiplicity of infection. DNA was extracted 48hrs after infection and primers 
specific for adeno-associated viral sequences were used. B, PCR amplification of 
adeno-associated viral DNA extracted from hepatic metastases of mice injected 
with adeno-associated viruses. Tumors were extracted 48hrs after injection, 
genomic DNA extracted and PCR amplification of viral-specific DNA was 
performed. 
A proof-of-principle experiment was performed in which mice were injected 
with highly metastatic LvM3b cells and a single dose of adeno-associated virus 
encoding miR-483-5p and miR-551a from a single transcript was injected 
intravenously 24hrs after colon cancer cells inoculation. A single therapeutic dose 
of AAV delivering both microRNAs were able to significantly reduced metastatic 
colonization (Fig. 4.7A). Therapeutic efficacy was also seen in mice injected with 
SW480 cells (Fig. 4.7B) and a primary patient-derived cell-line (Fig. 4.7C) In these 
experiments, there were no adverse phenotypic outcomes or pathological 
abnormalities in the treated mice. 
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Figure 4.7 | Adeno-associated viral delivery of miR-483-5p and miR-551a 
suppress liver metastasis by colon cancer cells. A, Liver metastasis in mice 
injected with LvM3b cells and treated with a single dose of 1 x 1012 AAV doubly 
expressing miR-483-5p and miR-551a one day after injection cells (n=6). B, Liver 
metastasis in mice injected with SW480 cells and treated with a single dose of 
AAV doubly expressing miR-483-5p and miR-551a one day after injection cells 
(n=4). Metastatic burden was monitored by bioluminescent imaging and mice 
euthanized at day 21 for LvM3b and day 28 for SW480. C, Metastatic burden in 
mice inoculated with a patient-derived primary colon cancer cell-line and treated 
with control AAV or AAV-miR. Representative H&E stained liver sections with 
liver metastases were shown. P values are based on one-sided Mann-Whitney 
test for non-Gaussian distribution. *p<0.05; **p<0.01. 
! 89
In mice injected with BEAS-2B immortalized lung epithelial cells that are prone 
to oncogenic transformation (Amstad et al., 1988; Pacurari et al., 2013), treatment 
with microRNA delivering AAV also did not result in spontaneous tumors, 
demonstrating the relatively safety of this single-dose AAV treatment in the 
context of immunodeficient mice (Fig. 4.8). However, given possible unforeseen 
pleiotropic effects of continued ectopic delivery of microRNAs (Grimm et al., 
2006), further extensive characterization with regards to adeno-associated viral 
delivery of microRNAs has to be performed prior to clinical evaluation in human 
patients (Garzon et al., 2010). 
Figure 4.8 | Adeno-associated viral delivery of microRNA does not result in 
oncogenic transformation in various tissues. H&E sections of indicated organs 
from mice treated with control or microRNA encoding AAV. 
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Small molecule inhibition of CKB and SLC6a8 suppress colon cancer 
metastasis 
As an alternative to adeno-associated viral delivery of miR-483-5p and miR-551a, 
which might have unforeseen pleiotropic effects, targeting of the downstream 
effector, CKB, using a small molecule inhibitor was performed. Cyclocreatine is a 
low-potency inhibitor of CKB. Therapeutic treatment of mice with cyclocreatine 
after colorectal cancer cell inoculation significantly reduced metastatic 
colonization, demonstrating proof-of-principle for targeting this kinase as a 
means of metastasis suppression (Fig. 4.9A). The modest but significant effect of 
cyclocreatine on metastasis suppression could be due to cyclocreatine being a 
relatively poor inhibitor of CKB (Lillie et al., 1993). A more potent inhibitor could 
potentially demonstrate a higher therapeutic efficacy. Treatment of mice 
inoculated with colon cancer cells with guanidinopropionic acid (GPA), a small 
molecule inhibitor of SLC6a8 was also able to significantly inhibit the formation 
of liver metastasis (Fig. 4.9B).  
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Figure 4.9 | Small molecule inhibition of CKB or SLC6a8 suppress metastasis 
by colon cancer cells. Liver metastasis in mice injected with 5 X 105 LvM3b cells 
and treated with cyclocreatine daily for two weeks (n>15). Liver metastasis in 
mice injected with 5 x 105 LvM3b cells and treated with GPA daily for three 
weeks (n=4). P values are based on one-sided Mann-Whitney test for non-
Gaussian distribution. *p<0.05; **p<0.01. 
Depletion of CKB and SLC6a8 in pancreatic cancer cells suppressed liver 
metastasis 
Liver metastasis is a common occurrence during the progression of pancreatic 
cancer. As pancreatic cancer cells will also experience hypoxia within the liver 
microenvironment, depletion of CKB and SLC6a8 in pancreatic cancer cells could 
possibly suppress liver metastasis by pancreatic cancer cells. Indeed knockdown 
of CKB and SLC6a8 in PANC1 cells (a K-RAS mutant human pancreatic cell-line) 
with multiple shRNAs, strongly suppressed their ability to metastasize to the 
liver (Fig. 4.10A, B). This preliminary finding suggested that CKB and SLC6a8, 
and their associated metabolic pathways, might broadly govern liver metastasis 
by other gastrointestinal cancers. Inhibition of this pathway in the clinic might 
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therefore provide therapeutic benefit to patients with pancreatic cancer as well as 
other gastrointestinal cancers. 
Figure 4.10 | Depletion of CKB and SLC6a8 suppress pancreatic cancer 
metastasis to the liver. A, Liver metastasis by pancreatic cancer cells, PANC1, 
with knockdown of CKB with two independent shRNA hairpins (n=5). B, Liver 
metastasis in mice injected with 5 X 105 PANC1 cells transduced with two 
independent SLC6a8 shRNAs (n=5). Metastatic progression was monitored by 
bioluminescent imaging. Mice were euthanized 35 days after injection and liver 
excised for bioluminescent imaging and gross morphology. P values are based 
on one-sided Mann-Whitney test for non-Gaussian distribution. ***p<0.001. 
Summary of Chapter IV 
This chapter presents evidence from archival clinical samples that corroborated 
the role of miR-483-5p and miR-551a as suppressors of colorectal cancer 
metastatic progression from primary tumors to liver metastases. MiR-483-5p and 
miR-551a expression was silenced in liver metastases relative to primary tumors. 
Consistent with experimental findings that CKB and SLC6a8 are promoters of 
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liver metastasis and are selected for during metastatic progression, liver 
metastases from patients had expressed higher levels of CKB and SLC6a8 across 
multiple clinical sets. Proof-of-principle therapeutic delivery of miR-483-5p and 
miR-551a using adeno-associated viral-vectors demonstrated efficacy in 
suppressing colon cancer metastasis, as did small molecule inhibition of CKB 
and SLC6a8. Depletion of CKB and SLC6a8 in a pancreatic cancer cell-line also 
suppressed pancreatic cancer liver metastasis, which suggested that therapeutic 
targeting of CKB and SLC6a8 in other gastrointestinal cancers might prevent 
liver metastasis. 
! 94
Chapter V: Summary and Perspectives 
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Overall Summary 
Colorectal cancer is one of the most prevalent cancers in the United States and 
contributes to almost 10% of all cancer deaths. Majority of patients die as a result 
of colorectal cancer cells metastasis to the liver (Siegel et al., 2014a; Siegel et al., 
2014b). Understanding the cellular and physiological basis of colorectal cancer 
metastasis is therefore of great interest to the medical and scientific community 
with regards to developing new therapies targeting this important step in 
colorectal cancer progression. 
This thesis describes the use of two complementary approaches to identify two 
microRNAs, miR-483-5p and miR-551a, as suppressors of colon cancer cell 
survival in the liver microenvironment and suppressors of metastatic 
colonization. Systematic dissection of the downstream effector pathways using in 
vitro cell culture, organotypic slice culture and in vivo experimental metastasis
systems identified CKB as a direct target and downstream effector of both 
microRNAs. Over-expression of CKB was sufficient to enhance metastasis, while 
depletion of endogenous CKB suppressed metastasis by colon cancer cells. 
Hypoxia was identified to be a relevant physiological stress during colorectal 
cancer metastasis to the liver and CKB was found to promote metastasis to the 
liver by enhancing cell survival in the hypoxic liver microenvironment.  
CKB belongs to a group of enzymes that readily modulate high-energy 
phosphate metabolite levels within the cell by catalyzing the transfer of a high-
energy phosphate group from phosphocreatine to ADP (Wallimann et al., 1992; 
Wyss and Kaddurah-Daouk, 2000). In the physiologically hypoxic environment 
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of the liver, maintenance of intracellular ATP levels by CKB resulted in enhanced 
colon cancer cell survival. This enables surviving cells to subsequently activate 
hypoxia response pathways that can result in successful completion of the 
metastatic cascade and liver colonization (Semenza, 2013).  Remarkably, colon 
cancer cells can release CKB extracellularly to take advantage of the ATP-rich 
extracellular milieu and liver-synthesized creatine to generate an exogenous 
source of phosphocreatine that can be further taken up by colon cancer cells 
through the SLC6a8 membrane transporter as an additional source of ATP for 
metastatic survival and progression (Fig. 5.1). 
Figure 5.1 | Model for the role of CKB during metastatic progression of 
colorectal cancer. Disseminated colon cancer cells arrive in the liver 
microenvironment through the hypoxemic portal circulation. Within the liver 
microenvironment, they experience hypoxic stress and ATP depletion. Cells that 
up-regulate CKB through loss of miRNAs, release CKB into the extracellular 
matrix where it converts available creatine and ATP into phosphocreatine that is 
then taken up by the cell to fuel metastatic survival and subsequent organ 
colonization. Colon cancer cells with higher levels of CKB also build up a larger 
pool of intracellular phosphocreatine that acts as a buffer against energetic stress. 
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In the final chapter of this thesis, clinical evidence was presented that supported 
the roles of miR-483-5p and miR-551a in suppressing colorectal cancer 
progression to liver metastases. A role for CKB and the transport protein SLC6a8 
during metastatic progression was supported by increased expression of CKB 
and SLC6a8 in human liver metastases compared to primary tumors. As the 
microRNAs and the effector proteins in the CKB network are clinically relevant, 
proof-of-concept therapeutic targeting of this pathway through adeno-associated 
viral delivery of the microRNAs and small molecule inhibition of CKB was 
investigated and demonstrated to be effective in vivo in mice.
In summary, this thesis presented the application of two unbiased approaches to 
identify a microRNA network that regulates colon cancer metastasis through 
CKB. CKB promotes colon cancer cell survival in the hypoxic liver 
microenvironment through modulation of high energetic metabolites intra- and 
extracellularly. The identified pathways were found to be clinically relevant and 
could potentially be therapeutically targeted, either through restoration of 
microRNA levels or small molecule inhibition of the effector proteins. 
Library-based identification of microRNAs that suppress colon cancer 
metastasis 
Recently, many investigators have used library-based screening approaches to 
identify molecular mediators of various biological processes during 
tumorigenesis and cancer progression (Eifert and Powers, 2012; Mohr et al., 2010). 
Molecular determinants of phenotypes such as in vitro cell proliferation in
different contexts, in vitro migration and invasion (Quintavalle et al., 2011) and
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drug sensitivity (Gupta et al., 2009) have been described through the use of 
library-based screening approaches. However, while identified mediators of the 
studied phenotypes can be characterized and further validated through 
downstream experiments, a caveat concerning some of the studies is that the 
initial screen was performed in an in vitro context that might not necessarily lend
itself to the appropriate in vivo physiological context. It is only recently that in 
vivo library based functional screens have been reported (Beronja et al., 2013;
Schramek et al., 2014). Because of the above caveat, there could be false negatives 
that are missed by in vitro screens, beyond the identified mediators that are
subsequently validated experimentally. A pre-determined selective pressure in 
vitro would also occlude the identification of novel mediators involved in aspects
of cancer progression that are not readily apparent in vitro.
As an approach to identify novel determinants of colon cancer liver colonization, 
an in vivo library screen of 661 microRNAs was performed through injection of
colon cancer cells directly into the liver parenchyma. To develop into a metastatic 
liver nodule, colon cancer cells would have to survive the stringent selective 
pressure of the liver microenvironment. The use of an in vivo platform for the
screen allowed for identification of microRNAs that when over-expressed, 
suppress colon cancer metastasis in vivo through pathways that are
physiologically relevant and potentially lend themselves to in vivo microRNA-
delivery based therapeutics. The identification of miR-483-5p and miR-551a in 
part through this screen, which mediated colon cancer cell survival under 
hypoxia, a physiological stress present in the liver microenvironment,
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demonstrated the utility of this in vivo strategy in highlighting previously
overlooked biological bottlenecks critical to colon cancer metastasis to the liver. 
In vivo selection for liver metastatic colon cancer cells
A caveat of functional over-expression screens is that the genes or microRNA 
that were overexpressed, might not be present at endogenously relevant levels in 
the studied tissues (Ashworth and Bernards, 2010; Schramek et al., 2014). In vivo
selection thus provides a means to identify mediators that are present at 
endogenously relevant levels. Isaiah Fidler first pioneered in vivo selection when
he performed in vivo selection for metastatic melanoma cells (Fidler, 1973).  In
recent years, in vivo selection had been used to identify molecular determinants
of breast cancer and melanoma metastasis to the lungs, as well as breast cancer 
metastasis to the bone and brain (Kang et al., 2003; Minn et al., 2005; Pencheva et 
al., 2012; Png et al., 2012; Tavazoie et al., 2008). A caveat of in vivo selection is that
observed expression changes between parental and in vivo-selected cell
populations might be over-represented by passenger genes that may not confer a 
biological function. However, in vivo selection lends itself well as a parallel
approach to a functional library screen—targets that are identified in a functional 
overexpression screen and whose endogenous expression levels are changed in 
in vivo selected lines will be higher confidence functional mediators that are
present at physiologically relevant levels. That mir-483-5p and miR-551a were 
identified through the convergence of both functional screens and in vivo
selection and had robust effects highlighted the complementarity of both 
approaches. 
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Regulation of CKB by miR-483-5p and miR-551a 
MicroRNAs have been extensively studied for their roles in tumorigenesis and 
cancer progression and have been shown to modulate well-known cellular 
phenotypes such as migration, invasion, proliferation and cell death through 
regulation of effector gene targets . While it is not uncommon for studies to focus 
on the identification of single gene transcripts targeted by particular microRNAs, 
it is recognized that microRNAs, through their binding to target sequences on 
different gene transcripts, can exert pleotropic effects by modulating divergent 
gene expression programs (Pasquinelli, 2012). Based on this effect, microRNAs 
can regulate the expression of multiple transcripts that do not necessarily 
converge on the same biological pathways. However, an alternative model could 
also hold true in which a single microRNA can regulate multiple transcripts that 
eventually converge on the same biological processes and phenotypes resulting 
in a very robust regulation of particular biological pathways by a single 
microRNA. More recently, a third model of microRNA-mediated regulation of 
biological processes emerged in which multiple microRNAs can coordinately 
converge on a few genes regulating a particular biological process. The 
advantage would be that dysregulation of one of a few microRNAs in a pathway 
would not necessarily disrupt the biological processes as extensively since the 
other microRNAs can still provide a layer of redundancy in terms of regulation. 
In the present thesis, miR-483-5p and miR-551a were identified to convergently 
target a functional effector, CKB. While miR-483-5p and miR-551a could regulate 
the level of other transcripts, in vivo loss-and-gain of function epistasis
experiments confirmed CKB to be an important downstream effector of both 
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microRNAs in the context of liver colonization by colon cancer cells. Given that 
an increase in CKB levels is sufficient to enhance metastasis by colon cancer cells 
and CKB expression is necessary for successful completion of the metastatic 
cascade, a network of multiple microRNAs targeting CKB would provide a layer 
of redundancy in preventing severe dysregulation of this pathway and 
suppressing metastatic colonization.  
The regulation of the above network is critical; in contrast to the multitude of 
pathways and genes that could contribute to a migratory and invasive 
phenotype, the specific enzymatic reaction converting creatine to 
phosphocreatine can only be catalyzed by a few other isoenzymes that are within 
the creatine kinase family, namely CKM, CKMT1 and CKMT2 (Wallimann et al., 
1992). CKMT1 and CKMT2 are ubiquitous mitochondrial creatine kinases whose 
subcellular localization is limited to the mitochondrion, where they perform a 
role in transferring ATP (generated from oxidative phosphorylation) from 
mitochondria to the cytosol of cells. CKM is the only alternative cytosolic 
creatine kinase that could perform the same cellular role as CKB. However, as 
earlier studies had described a lack of CKM expression in colonic tissues (Trask 
et al., 1988; Urdal et al., 1983), CKB remains a critical enzyme in colon cancer cells 
that had to be tightly regulated to prevent dysregulation of 
creatine/phosphocreatine metabolism and metastatic progression to the liver. 
That extracellular CKM had not being extensively detected in the serum of 
patients with advanced cancer also indicates the possibility that the mechanism(s) 
involved in CKB release are unique to CKB and could be an alternative pathway 
through which CKB’s functions are regulated. 
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CKB and initial seeding of colon cancer cells into the liver microenvironment 
Colon cancer cells cannot easily circumvent the physiological challenges 
presented by the liver microenvironment.  Earlier studies investigating the 
efficiency of colon cancer cell metastasis to the liver demonstrated that only 0.1% 
of all colon cancer cells that eventually arrive successfully at the liver go on to 
develop metastases (Sugarbaker, 1993; Weiss et al., 1986). The stresses 
encountered by colon cancer cells during liver colonization can only be 
understood by an appreciation of the physiological functions and architecture of 
the liver. 
The liver is a complex organ that is responsible for a varied number of 
physiological functions required for organismal homeostasis. The enormous 
functional capacity of the liver is surprisingly mediated by a minimal number of 
cell-types comprising parenchymal cells (hepatocytes) and non-parenchymal 
cells consisting of sinusoidal endothelial cells, Kupffer cells and hepatic stellate 
cells. The variation in cellular function is achieved through functional 
specialization of cells based on their location with respect to the direction of 
blood flow through the organ and oxygenation levels (Jungermann and 
Kietzmann, 1996, 2000). This division of biochemical functions is known as ‘liver 
zonation’. Functional groups of hepatocytes can be broadly grouped into cells at 
the periportal region experiencing relatively higher levels of oxygenation 
(considering that blood reaching the liver is already hypoxemic in nature) and 
cells at the perivenous region which is hypoxic in nature. Oxygen pressure at the 
perivenous region can fall as low as 5-10mmHg, corresponding to 0.5-1% oxygen 
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levels due to consumption by metabolically active hepatocytes present upstream 
(Arteel et al., 1995). Perivenous hepatocytes actively undergo glycolysis as their 
main source of cellular energy. Colon cancer cells that initially arrived at the liver 
will eventually get arrested near the perivenous region where they experience 
acute hypoxia. Empirical evidence from in vitro co-culture and tissue-mimetic
studies had also described hepatocytes to consume oxygen at a rate of 10-40 
times that of colon cancer cells, resulting in an hypoxic microenvironment 
experienced by colon cancer cells during co-culture experiments (Jiang et al., 
2013). 
While hypoxia can result in depletion of ATP reserves and cell death, it is widely 
accepted that cancer cells utilize glucose during glycolysis as a major source of 
cellular ATP. In the context of the above-discussed liver microenvironment, 
where colon cancer cells are arrested at the hypoxic perivenous region, an 
understanding of hepatic glucose metabolism is important to understand the 
limitation of glycolysis in fueling metastatic cell survival during initial 
dissemination to the liver prior to any adaptive response to the hypoxic 
environment. 
An important homeostatic role performed by the liver is the regulation of blood 
glucose levels through integration of glucagon and insulin signaling. Excess 
glucose is taken up by hepatocytes to synthesize glycogen (glycogenesis) that can 
be subsequently converted to glucose (gluconeogenesis) when required. 
Periportal and perivenous hepatocytes are responsible for very distinct roles 
during glycogenesis and gluconeogenesis. Particularly pertinent to colon cancer 
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cells at the perivenous regions are the roles of perivenous hepatocytes during 
these two processes. During glycogenic phase, perivenous hepatocytes will 
actively take up glucose to synthesize glycogen. Excess glucose is consumed by 
perivenous hepatocytes via glycolysis, with the release of lactate that travels 
through the circulation to arrive at the periportal hepatocytes where they are 
converted to glucose via gluconeogenesis for glycogenesis. Colon cancer cells 
that are newly disseminated to the liver therefore encounter intense competition 
for the absorption of glucose from perivenous hepatocytes undergoing 
glycogenesis and glycolysis; in vivo measurements of glucose uptake by
hepatocytes had been determined to be as high as 0.61µM/min/g (Jungermann 
et al., 1982). In contrast, glucose uptake rates of established tumors of various 
cancer cell-types had been reported to vary between 0.21-0.43µM/min/g 
(Kallinowski et al., 1989; Kallinowski et al., 1988). Freshly disseminated cells 
arriving at the liver microenvironment would possibly have even lower glucose 
uptake rate prior to up-regulation of glucose transporters. Taking into 
consideration the relative abundance of hepatocytes compared to disseminated 
colon cancer cells, these factors contribute to a scenario in which colon cancer 
cells are severely out-competed for glucose by hepatocytes. 
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Figure 5.2 | Liver metabolism and colorectal cancer cells metastasis. Colon 
cancer cells arriving at the liver via the hypoxemic portal circulation experience 
progressively lower levels of oxygenation and glucose availability as they 
competes with hepatocytes for glucose and oxygen. 
Given the above context  (Fig. 5.2), CKB expression is beneficial to colon cancer 
cells. Increased CKB expression will allow for increased levels of 
phosphocreatine within colon cancer cells that will be a reservoir of ATP that can 
be rapidly utilized for when colon cancer cells first arrive at the liver. The release 
of CKB into the extracellular space will also allow for the scavenging of 
extracellular ATP in the form of phosphocreatine that can be an additional source 
of ATP that fuel cell survival and metastatic progression until further adaptation. 
This latter function of CKB described within this thesis requires that 
concentrations of extracellular ATP and creatine in the pericellular environment 
of colon cancer cells be sufficient for the reaction to proceed. Previous studies 
outside the context of cancer progression have reported resting serum creatine 
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levels to be approximately 50-100μM, while extracellular ATP levels are reported 
to be extremely low in healthy tissues, with concentrations of extracellular ATP 
to be in the nanomolar range. In the context of cancer progression, increased 
levels of extracellular ATP within the immediate microenvironment of cancer 
cells have been reported to be in the range of hundreds of micromolar (Pellegatti 
et al., 2008), while ADP levels were reported to be an order of magnitude lower, 
in part due to the expression of ecto-nucleotidases by cancer cells that readily 
converts ADP to adenosine. Earlier investigations into the kinetics of creatine 
kinases in vitro had established Michaelis constants of creatine kinases for ATP
and creatine to be in the order of micromolars (Valdur A et al., 1998). While the 
extracellular milieu of cancer cells is more complex than the defined reaction 
buffers utilized in in vitro biochemical assays, given the relative high
concentrations of extracellular ATP and creatine, the generation of 
phosphocreatine from ATP and creatine within the extracellular 
microenvironment of cancer cells is energetically favored. However, biological 
sensors for the detection of phosphocreatine without the need for biochemical 
assays or isolation of bulk biological fluids would have to be developed for more 
sensitive and timely detection of phosphocreatine synthesis within the tumor 
microenvironment. 
The role CKB plays in colon cancer cell survival during the initial phase of 
metastatic seeding in the liver is critical as cells that survive the initial hypoxia 
would be able to activate additional pathways involved in energy homeostasis 
and generation such as activation of the AMPK (DeBerardinis et al., 2008; Hardie 
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et al., 2012; Inoki et al., 2012; Jeon et al., 2012). The surviving cells would also 
have engaged hypoxia-activated pathways that are pro-metastatic through the 
HIF-1A transcriptional pathway and can progress to aggressively colonize the 
liver (Chiang and Massagué, 2008; Kaelin and McKnight, 2013; Semenza, 2011). 
Cells that survive the barrier presented by the liver microenvironment through 
CKB expression are therefore selected for aggressive metastatic progression. 
CKB during metastatic progression 
While the role of CKB during metastatic initiation in the liver was investigated in 
the present thesis, CKB could also play a role during metastatic progression after 
macro-metastases have been established. During metastatic progression, an 
intracellular pool of phosphocreatine that functions as a readily accessible source 
of ATP through CKB can provide an energetic buffer for when ATP generated 
through glycolytic pathways are insufficient for the cells’ energetic needs. Such 
stresses could occur when the growing metastases outstrip blood supply or when 
challenged by cytotoxic drugs that deplete intracellular ATP levels of cells. When 
cancer cells are challenged with such an acute stress that depletes intracellular 
ATP, additional ATP can be generated from phosphocreatine rapidly as a buffer 
until an adaptive cellular response. 
Intracellular ATP levels are tightly regulated even as the energetic needs of 
cancer cells are tightly balanced against a requirement for biosynthetic materials 
through modulation of glycolysis (Locasale and Cantley, 2011). Intracellular ATP 
can function as an allosteric inhibitor of glycolytic process through inhibition of 
fructose-6-phosphokinase. CKB expression can thus allow for diversion of excess 
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ATP towards phosphocreatine, allowing glycolysis to continue for generation of 
biosynthetic substrates required during metastatic progression.  
With the possibility that CKB could be beneficial during the later stages of 
metastatic progression, it would be interesting to investigate the effect inhibiting 
or depleting CKB has on metastatic progression after macro-metastases have 
been established. A recent study had also demonstrated increased intracellular 
ATP levels to be important for enhanced drug resistance in colon cancer cells 
(Zhou et al., 2012). The effect of CKB inhibition and decreasing intracellular ATP 
and phosphocreatine levels on potentiating the effects of cytotoxic drugs that 
stress cancer cells energetically could also be investigated as a possible 
therapeutic strategy against metastatic progression. 
Functional consequences of extracellular catalysis by CKB 
CKB protein levels or enzymatic activity as a serum marker for malignancies 
have been described in early clinical studies (Huddleston et al., 2005; Rubery et 
al., 1982). The presence of CKB in the serum was attributed to inconsequential 
release by damaged and dying cells during malignant progression. However, 
functional studies described in the current thesis demonstrated that extracellular 
CKB released by colon cancer cells within the liver microenvironment could 
perform its enzymatic function using substrates available extracellularly to 
generate phosphocreatine to enhance colon cancer metastasis. In addition to 
phosphocreatine, a product of CKB catalysis is ADP, which is generated from 
ATP.  
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While the functional aspects of ATP conversion to ADP by CKB was not 
investigated in the present thesis, numerous studies by other investigators have 
demonstrated the relevance of purinergic signaling to cancer progression (Di 
Virgilio, 2012; Stagg and Smyth, 2010). The presence of ATP in tumor 
microenvironment has been demonstrated to initiate innate immune responses 
that can be suppressive to tumor growth (Aymeric et al., 2010). However, 
conversion of ATP to ADP, and finally adenosine by a series of membrane-bound 
ectonucleotidase can result in an immune-suppressive effect that in turn could be 
conducive to tumor progression (Deaglio et al., 2007; Jin et al., 2010). ADP 
generation as a result of CKB catalysis could therefore be a source of adenosine 
that can mediate immune-suppressive effects. As xenograft models of colon 
cancer progression in immunodeficient mice were use in the current study, the 
effects of CKB-mediated purinergic signaling through extracellular ADP and 
adenosine production were not investigated. However, future studies in 
immunocompetent mouse models will be useful for dissecting the contribution 
of CKB towards immune evasion by colon cancer cells through modulation of 
purinergic signaling. 
An expanded functional space for intracellular enzymes 
The secretome of cancer cells have been the subject of many investigations 
(Paltridge et al., 2013). Unbiased proteomic studies of extracellular proteins from 
cancer cells have reported the presence of multiple intracellular enzymes with no 
known secretory routes and consequently have attributed the presence of 
intracellular enzymes as artifacts arising from cellular damage and death and not 
further investigated. Similarly, prior to the work described in this thesis, the 
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presence of CKB in the serum of cancer patients was considered a consequence of 
dying cells with no functional role during cancer progression.  
The identification of CKB as an intracellular enzyme that also plays an 
extracellular catalytic function therefore expanded the functional space of 
canonical intracellular enzymes, as there could be other intracellular enzymes 
that may also play an extracellular role during cancer progression. Of particular 
interest are enzymes involved in different enzymatic reactions of glycolytic 
pathways, as metabolites arising from glycolytic pathways are abundant in the 
immediate milieu of primary nodules or metastases. Lactate dehydrogenase is a 
prominent intracellular enzyme responsible for the reversible conversion of 
pyruvate to lactate. Similar to CKB, high expression of lactate dehydrogenase has 
been associated with poor prognosis in cancer patients and the presence of 
lactate dehydrogenase have been described in literature as a marker of cell death 
during tumor progression. It is well established that extracellular lactate is 
abundant in the extracellular space of malignancies. It is therefore possible that 
extracellular lactate dehydrogenase could utilize exogenous lactate to generate 
pyruvate that could in turn be beneficial to cancer progression. Interestingly, 
early studies in rabbits have described physiological release and activity of 
lactate dehydrogenase in the oviducts (Georgiev et al., 1970) and postulated an 
extracellular role for lactate dehydrogenase during early embryogenesis when 
substrates for growth are limited, paralleling the context of early metastatic 
growth. It would therefore be of biological interest to investigate if extracellular 
lactate dehydrogenase has a functional role during metastasis. 
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In addition to lactate dehydrogenase, another key glycolytic enzyme, pyruvate 
kinase M2, has also been described to be present in the serum and plasma of 
cancer patients (Hugo et al., 1999) and have recently been reported to have 
functional effects on tumor progression through modulation of angiogenesis (Li 
et al., 2014). While the mechanistic pathway through which extracellular 
pyruvate kinase M2 promotes angiogenesis remains to be identified, the above 
recent study is yet another example of how intracellular enzymes can have non-
canonical roles extracellularly. 
With an expanded functional space for intracellular enzymes, there is a resultant 
expansion of the therapeutic window against intracellular enzymes. Therapeutic 
targeting of key intracellular enzymes using membrane-permeable inhibitors in 
diseases had been limited by accompanying toxicity in normal tissues. The 
expansion of therapeutic space as a result of extracellular roles played by 
intracellular enzymes will allow for the design of non-membrane permeable 
inhibitors that can target extracellular enzymes released by cancer cells while 
avoiding the deleterious effects of inhibiting their intracellular counterparts in 
normal tissue. The use of neutralizing antibodies against these extracellular 
enzymes is also a potential avenue for highly specific inhibition of these enzymes. 
Extracellular release of intracellular enzymes 
An outstanding question remains with regards to how CKB and potentially, 
other intracellular enzymes with no known routes of secretion are released by 
cancer cells. Preliminary experimental evidence presented in this thesis indicated 
that CKB secretion is unlikely to occur through known canonical secretory 
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pathways involving N-terminal signal peptides, nor through exosomes. The 
mechanisms by which intracellular enzymes such as CKB are released into the 
extracellular space by cancer cells remain to be elucidated. 
In recent years, a new class of vesicles known as ectosomes has been described 
and is gaining interests among investigators (Cocucci and Meldolesi, 2015). 
Ectosomes are variable-sized vesicles that bud directly off the plasma 
membranes of cells and can release their contents into the extracellular space. 
They are also able to persist intact before fusion with the plasma membranes of 
other cells, releasing their contents into cells, which results in the intercellular 
transfer of proteins and metabolites into the recipient cell. Immunohistochemical 
staining of archival tissues described in this thesis revealed the presence of CKB 
in the vicinity of plasma membranes of cancer cells in addition to the cytosolic 
space. The possible release of CKB through ectosomal budding of vesicles could 
be investigated in further studies. Regardless of the mechanisms responsible for 
the extracellular release of CKB and other intracellular enzymes, identifying the 
cell biological pathways involved may also have potential therapeutic benefits as 
inhibition of CKB release could also suppress metastatic progression. The 
identification of additional intracellular enzymes with malignant extracellular 
functions will also expand the therapeutic space for metastatic cancer. 
Therapeutic targeting of the miR-483-5/miR-551a/CKB/SLC6a8 functional axis 
Multiple proof-of-principle therapeutic experiments presented in the current 
thesis demonstrated the utility of targeting the miRNAs/CKB/SLC6a8 
functional axis in preventing the establishment of colon cancer metastases. 
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Adeno-associated viral delivery of genes has in recent years been shown to be 
safe and promising in the treatment of various human diseases such as 
hemophilia, having successfully undergone clinical trials with minimal side 
effects (Kotterman and Schaffer, 2014; Nathwani et al., 2011). Therapeutic 
delivery of microRNAs in mouse models of hepatocellular carcinoma had also 
proved to be efficacious (Kota et al., 2009). Adeno-associated viral vectors of 
different serotypes exhibit tropisms for different organs, with most serotypes 
showing some degree of affinity for hepatic tissue. A recently developed, 
recombinant serotype, AAV-DJ was shown to have increased efficiency in 
transducing hepatocytes compared to wild-type virus, and also displayed 
increased infectivity towards multiple other cell-types in vitro (Grimm et al.,
2008). The availability of this recombinant adeno-associated virus allowed for 
testing of the utility of therapeutic microRNA delivery to colon cancer cells in 
vivo in the liver. In proof-of-concept experiments, a single dose of recombinant
AAV-DJ viral particles was able to therapeutically deliver miR-483-5p and miR-
551a to colon cancer cells in the liver and suppressed the formation of colon 
cancer metastases with no noticeable side effects in treated mice. While the 
experiments demonstrated that delivery of microRNAs early after cancer cell 
dissemination can result in suppression of metastases, a caveat remains that 
continuous dissemination of colon cancer cells from remnant primary tumors can 
negate the efficacy of single-dose administration of adeno-associated viruses. 
This concern can be addressed using xenograft orthotopic models of colon cancer 
and treatment of mice with multiple doses of adeno-associated viruses after 
surgical resection of the primary tumor. While there were no observable side 
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effects in mice treated with a single dose of adeno-associated virus, the effects of 
multiple administrations of adeno-associated viruses delivering the microRNAs 
should also be investigated to ensure there are no deleterious side effects from 
continued overexpression of either miR-483-5p or miR-551a in normal tissues. 
As an alternative to delivery of microRNAs by adeno-associated viruses, 
therapeutic inhibition of CKB was demonstrated in the current work. The modest 
effect seen could be a result of the low potency of the available inhibitor, 
cyclocreatine. Improvement of the inhibitor through crystal structure guided 
design might improve the therapeutic effect. While it is possible that normal 
tissues with lower energetic needs are less susceptible to CKB and creatine 
kinases inhibition, the effects of more potent inhibitors or longer durations of 
inhibitor administration have to be thoroughly investigated. The extracellular 
role of CKB during metastatic progression also allows for the design of non-
membrane permeable inhibitors that can potentially have a lower risk of 
undesirable side effects. 
Another targetable aspect of the CKB/SLC6a8 axis is the SLC6a8 membrane 
transporter downstream of the extracellular catalytic reaction performed by CKB. 
As preliminary experiments using a small molecule inhibitor of SLC6a8 
demonstrated that inhibition of SLC6a8 was also able to potently suppress liver 
metastases, designing of more potent small molecule inhibitors targeting SLC6a8 
would provide additional avenues for targeting this pro-metastatic pathway in 
colorectal cancer. Recently, the use of antibodies to block activity of membrane 
transporters and channels have been investigated and shown to be effective in 
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inhibiting transporters and channels’ activities by preventing conformational 
changes in these proteins after binding to specific epitopes on the surface of the 
membrane protein (Fiorio Pla et al., 2012). The development of neutralizing 
antibodies targeting SLC6a8 can therefore provide an alternative and highly 
specific therapy against metastatic colorectal cancer. 
Relevance of CKB and SLC6a8 to metastatic progression in other 
gastrointestinal cancers 
Liver metastasis is a common occurrence during progression of gastrointestinal 
cancers such as pancreatic and gastric cancers as these cancer cells can be 
disseminated via similar hematogenous routes involving the portal circulation. 
These gastrointestinal cancer cells will encounter the same hypoxic and energetic 
stress in the liver microenvironment as colon cancer cells. The results from this 
study arising from depletion of CKB and SLC6a8 in pancreatic cancer cells 
indicated that in addition to colon cancer, CKB and SLC6a8 might also be 
important for liver metastatic colonization by other gastrointestinal cancers, 
warranting further investigation in mouse models of pancreatic and gastric 
cancer. In particular, because of the availability of genetic mouse models of 
pancreatic cancer that could accurately mimic cancer progression in human 
patients, including the development of liver metastases, conditional knockout of 
CKB and SLC6a8 in these genetic mice models could further confirm the 
importance of CKB and SLC6a8 in gastrointestinal cancer progression. 
Therapeutic targeting of these effector proteins in pancreatic and gastrointestinal 
cancers through small molecule or antibody inhibition could therefore prevent 
metastatic progression in patients with other gastrointestinal cancers.  
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Conclusion 
The present thesis describes the use of two unbiased complementary approaches 
to identify regulators of colon cancer liver metastasis. Mir-483-5p and miR-551a 
were identified as suppressors of liver metastasis. CKB, a promoter of liver 
metastases was identified as a direct downstream target and effector of both 
microRNAs. CKB promoted liver metastases through modulation of intra- and 
extracellular energetics. In addition to regulating intracellular levels of ATP, it 
can be released by cancer cells to scavenge high-energy phosphate metabolites 
from exogenous sources of creatine and ATP. SLC6a8, a membrane transporter 
protein responsible for transport of creatine compounds, was found to be a 
critical effector downstream of the extracellular effects of CKB. The microRNAs, 
CKB and SLC6a8 were found to be clinicopathologically associated with 
metastatic progression of colon cancer patients and proof-of-principle 
therapeutic targeting of the pathway identified herein demonstrated therapeutic 
efficacy. This thesis revealed molecular mechanisms underlying liver metastases 
by colon cancer, and possibly other gastrointestinal cancers and may provide 
insights for future development of therapeutics for the treatment of metastatic 
gastrointestinal cancers. 
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Materials and Methods 
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Animal studies 
All animal work was conducted in accordance with a protocol approved by the 
Institutional Animal Care and Use Committee (IACUC) at The Rockefeller 
University. 5-6 weeks old age-matched male NOD-SCID mice were used for 
organotypic slice culture, intrahepatic colonization, liver metastasis assay and 
primary tumor growth assays involving LS174T, SW620, WiDR, LvM3a and 
LvM3b cell-lines. 5-6 weeks old age-matched male NOD/SCID gamma male 
mice were used for liver metastasis assays for the SW480 and PANC1 cell-lines. 
5-6 weeks old age-matched male athymic nude mice were used for experiments 
involving BEAS-2B mice. For all experiments involving anesthesia and surgery, 
mice were monitored after surgery to ensure recovery from anesthesia before 
returning to clean cages. Breeding pairs of all mice strains were originally 
obtained from Jackson Laboratories and bred in house to establish colonies for 
experiments, with supplemental purchase from Jackson Laboratories when 
necessary. 
In vivo selection
1 x 106 LS174T cells expressing a luciferase reporter were suspended in a 20ul 
volume of 1:1 PBS/Matrigel mixture and injected directly into the livers mice 
(described in detail below). Colon cancer liver nodules were allowed to develop 
over a period of 3-4 weeks and monitored by bioluminescence imaging. Nodules 
formed were excised and dissociated by collagenase and hyaluronidase digestion 
(described in detail below) into single cell suspensions. The cells were allowed to 
expand in vitro before re-injection into mice. After three iterations of in vivo 
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selection, highly metastatic LvM3a and LvM3b derivative cell-lines were 
established from nodules obtained from independent mice. 
Intrahepatic injection for in vivo selection and liver colonization
Each mouse was first anesthetized with injection of ketamine/xylazine solution 
into the peritoneal cavity. When the mouse was deeply anesthetized (confirmed 
by lack of reflex response after pinching of hind legs), the fur above the abdomen 
wall was shaved and the shaved abdomen wall scrubbed with Betadine and 70% 
alcohol. A 15mm incision was made through the skin and peritoneum just below 
the sternum of the mouse to expose the liver. The left lobe of the liver was gently 
pulled out and stabilized with a pair of forceps and cells in a 20µL volume of 1:1 
PBS/Matrigel mixture were injected slowly using a 28-gauge needle attached to a 
1/2cc insulin syringe (Becton Dickinson). Blanching of the liver at the site of 
injection without reflux of injected cells indicated a successful injection. The 
needle was retracted slowly and a Q-tip placed over the site of injection with 
gentle pressure for about 30 seconds to prevent bleeding and spillage of injected 
cells. The left lobe was then returned to its original location and the peritoneum 
of the mouse closed with surgical 6-0 sutures (Roboz) and the skin closed with 
9mm wound clips (Roboz). 
Intrasplenic injection for liver metastasis assays and organotypic slice culture 
Each mouse was first anesthetized as described above. The left flank of the 
anesthetized mouse was shaved and scrubbed with Betadine and 70% alcohol. A 
10mm incision was then made in the skin and peritoneum just below the ribcage 
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of the mouse to expose the spleen. The spleen was gently exteriorized with a pair 
of forceps and stabilized. 5 x 105 Cells in 50µL volume of PBS were injected 
slowly using a 28-gauge needle attached to a 1/2cc insulin syringe. A blanching 
of the spleen without reflux of injected cells indicated a successful injection. The 
needle was retracted slowly and a Q-tip placed over the site of injection with 
gentle pressure to prevent bleeding and leakage of the injected cells. After 30 
seconds, the spleen was removed using a cautery and the peritoneum of the 
mouse closed with surgical 6-0 sutures (Roboz) and the skin closed with 9mm 
wound clips (Roboz). 
Retro-orbital injection of luciferin and DEVD-luciferin for bioluminescent 
imaging 
Each mouse was anesthetized using an isoflurane anesthesia chamber. After 
anesthesia, the mouse was placed its left flank and restrained using the thumb 
and index finger of the non-dominant hand. At the same time, the index finger 
and thumb was used to draw back the skin below the right eye of the mouse. 
100µL luciferin substrate (Perkin Elmer) was then injected using a 28-gauge 
insulin needle on a 1cc syringe into the retrobulber sinus of the mouse. For in 
vivo caspase activity bioluminescent imaging, 100µL of amino-DEVD-luciferin
substrate (15mg/mL) (Promega) was injected for bioluminescent imaging. After 
imaging with DEVD-luciferin, regular luciferin substrate (15mg/mL) was 
injected and imaging performed to obtain a normalization signal. The needle was 
then retracted slowly and the anesthetized mouse can be placed into the IVIS 
imaging system for bioluminescent imaging. Mice are imaged with their 
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abdominal facing up, and 30s after injection of luciferin. Images are taken with 
exposure times ranging from 5s to 5min dependent on metastatic burden to 
avoid saturation of CCD camera sensor, leading to inaccurate measurements. 
Tail vein injection for delivery of adeno-associated viral particles 
Intravenous tail vein injection was used for delivery of adeno-associated viral 
particles. Mice inoculated with colon cancer cells were randomized for treatment. 
Each mouse was restrained using a restrainer (Braintree Scientific) designed for 
tail vein injection. The tail of the moue were then gently warmed in 37 degree 
Celsius water, and wiped with 70% alcohol. 1 x 1012 purified adeno-associated 
viral particles in 150µL of PBS were then injected into the lateral tail vein of the 
mouse using a 27 1/2 -gauge needle attached to a 1cc syringe. A paling of the 
vein and noticeable delivery of PBS up the tail indicated a successful injection. 
The needle was retracted slowly and a kim-wipe was used to exert gentle 
pressure on the site of injection to stop the bleeding. The mouse was released 
after 30 seconds. 
Subcutaneous injections for primary tumor growth assays 
Each mouse was first anesthetized as described above. 1 x 106 cells were 
suspended in 100µl of 1:1 PBS:Matrigel mixture and injected into the 
subcutaneous flanks of the anesthetized mouse using a 27-gauge needle on a 1-cc 
syringe. Tumor growth was measured using digital calipers starting 7 days after 
injection. Each mouse was anesthetized using an isoflurane anesthesia chamber. 
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Palpable tumors were then grasped and measured. Volume of the tumors were 
calculated using the formula, Volume = (width)2 x (length)/2. 
Liver extraction and tumor nodule extraction 
Each mouse was first deeply anesthetized with a lethal dose of 
ketamine/xylazine solution. After confirmation of anesthesia, the fur above the 
abdomen wall of the mouse was shaved and the abdomen scrubbed with 
betadine and 70% ethanol. A 30mm incision was then made and the liver 
exteriorized. The liver of the mouse was then cut free of the abdominal cavity 
and washed gently with PBS. It could then be used for downstream experiments. 
If required, metastatic nodules in the liver were excised from the liver, washed 
with PBS and used for downstream experiments. 
Tumor nodule dissociation into cells for culture 
Each excised tumor nodule was first washed twice in PBS supplemented with 
penicillin-streptomycin, gentamicin and amphotericin B antibiotics. After 
washing, the tumor nodule was minced up as finely as possible with a pair no. 10 
surgical scalpels and re-suspended in 15mL of antibiotics-supplemented PBS. 
The minced tumor nodule was then collected by centrifugation at 800g for 5min. 
The PBS was removed and the nodule re-suspended in ACK buffer (Lonza) for 
lysis of residual red blood cells. After 10min incubation at room temperature, the 
minced nodule was collected by centrifugation and re-suspended in enzymatic 
digestion media (300u/mL Collagenase, 1u/mL Dispase, 0.25mg/mL 
Hyaluronidase, 24u/mL DNAseI; Worthington Biochemicals) and incubated 
with gentle agitation for 2hrs at 37 degree Celsius. After enzymatic digestion, 
! 123
cells were collected by centrifugation and incubated in 5mL trypsin-EDTA for 
10min at 37 degree Celsius. After trypsin digestion, cells were collected again by 
centrifugation, re-suspended in cell culture media, and filtered successively 
through 70µm and 40µm cell strainers to remove undigested debris and plated 
onto cell culture plates. Freshly plated cells were monitored daily for 
contamination and tested for mycoplasma contamination before transition into 
routine culture. 
Tumor nodule homogenization for western-blot 
Tumor nodules up to 125mm3 in size were excised and washed in PBS before 
immersion in 3mL of chilled RIPA buffer (Amersham) with protease inhibitors 
(Roche) on ice. A hand-held rotor-stator homogenizer was used to homogenize 
the tumor. After thorough homogenization, the mixture was incubated on ice for 
30min, before centrifugation at 15,000g for 10min to clear the supernatant. The 
supernatant was then used for western-blot after quantification with BCA kit 
(Pierce). 
Serum collection from mice 
Each mouse was first deeply anesthetized with a lethal dose of 
ketamine/xylazine solution. After anesthesia, the chest of the mouse was shaved 
and scrubbed with betadine and 70% ethanol. The chest cavity of the mouse was 
then quickly cut open and the heart exposed. Whole blood was collected from 
the mouse via cardiac puncture using a 27-gauge needle attached to a 1cc syringe. 
Up to 500µL of blood can be collected. After collection, the blood was allowed to 
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clot for 30min at room temperature before centrifugation to separate the serum 
from the blood clot. Collected serum was then stored at -20 degree Celsius. 
Cyclocreatine treatment of mice 
One day after inoculation of colon cancer cells into mice, injected mice was 
randomized and treated mice were injected with 10mg of cyclocreatine in 350μL 
of PBS via intra-peritoneal injection. Control mice received 350μL PBS placebo 
injections. Treatment was performed daily for 2 weeks until the mice were 
euthanized. 
Guanidinoproprionic acid treatment of mice 
One day after inoculation of colon cancer cells into mice, injected mice was 
randomized and treated with either 200μL PBS or 0.5M GPA in 200μL PBS daily 
for three weeks. The treatment was delivered via intra-peritoneal injections. 
Implantation of osmotic pumps 
Each osmotic pump (Alzet) was loaded with PBS or 1M-phosphocreatine 
solution according to manufacturer’s protocol. Briefly, for each pump, a blunt-
end loading tip was attached to a 1cc syringe and solution to be loaded was 
slowly injected into the reservoir of each pump using the syringe. After loading, 
the pump was capped and primed overnight by incubation in a warm saline 
solution at 37 degree Celsius. On the day of surgery, osmotic pumps were 
inserted into the peritoneal cavity of anesthetized mice. Depleted osmotic pumps 
were removed 7 days after implantation to prevent discomfort to mice. 
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Organotypic slice culture 
Cells were passaged such that they were 60% confluent at the start of the assay. 
On the day of slice culture preparation, cells were labeled by addition of either 
cell tracker red or green (Life Technologies) for 45min at 37°C. During incubation, 
tissue culture inserts (30mm, 0.4um; Millipore) was placed in 35mm tissue 
culture dishes and 1.1mL of liver media (Williams media E with hepatic culture 
supplement pack; Gibco) was added. The media from cell tracker labeled cells 
was then removed and replaced with fresh culture media and the cells were 
incubated for 30min at 37°C to ensure proper labeling. Cells were then prepared 
collected by trypsin digest from the cell culture plates and inoculated into mice 
by intrasplenic injection. After inoculation, mice were euthanized and liver 
excised as described above. Excised livers were washed gently with PBS 
supplemented with antibiotics and chopped into 150um slices using a tissue 
chopper (McIlwan). The slices were washed with antibiotics-supplemented PBS 
prior to transfer onto the tissue culture inserts using sterile transfer pipettes. 
Seeding of cells into within liver slices were confirmed by fluorescent light 
microscopy. Liver slices were cultured and media replaced daily until fixation 
with 4% paraformaldehyde for two-photon microscopy. 
Cell culture 
The 293T, LS174T, SW480, SW620, WiDR, PANC1 and BEAS-2B cell-lines were 
purchased from ATCC. 293T, LS174T, WiDR and PANC1 cells were cultured in 
DMEM media (Life Technologies) supplemented with 10% FBS (Sigma-Aldrich), 
sodium pyruvate (Life Technologies), L-glutamine (Life Technologies), 
amphotericin B (Lonza) and penicillin-streptomycin (Life Technologies). SW480 
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and SW620 cells were cultured in McCoy’s 5A media (Life Technologies) 
supplemented with the above cell-culture supplements. BEAS-2B were cultured 
in BEGM media (Lonza) which was supplemented with pre-aliquoted BEGM 
bullet kit (Lonza) with Hydrocortisone, hEGF, Epinephrine, Transferrin, Insulin, 
Retinoic Acid, Triiodothyronine and Gentamicin. For phosphocreatine pre-
treatment, cells were treated with 10mM phosphocreatine for 24hrs in media 
supplemented with 0.2% FBS prior to experiments. For cyclocreatine pre-
treatment, cells were treated with 10mM cyclocreatine for 48hrs. For hypoxic cell 
cultures, cells were cultured in 1% oxygen within a modular hypoxia chamber 
(Billups-Rothenberg). 
Generation of lentivirus, retrovirus, knock-down and over-expressing cells. 
For generation of lentivirus delivering shRNAs or over-expression vectors, 293T 
cells were seeded onto 10cm plates such that cell confluency will be 
approximately 70% the next day. 3µg each of pRSV-Rev, pCMV-VSVG-G and 
pCgpV packaging vectors (Cell Biolabs) were co-transfected with 9µg the 
appropriate pLKO-shRNA or pLenti-overexpression plasmids using 45µl of 
Lipofectamine 2000 in antibiotic-free media. After 16hrs, the media was replaced 
with fresh antibiotic-free media. After 24hrs, virus-containing supernatant was 
collected and centrifuged for 10min at 800g before being filtered through a 
0.45µm filter. For generation of over-expression retrovirus, 293T cells were 
seeded as described above. On the day of transfection, 12µg of the appropriate 
over-expression vector was co-transfected with 12µg of Pol/Gag and 6µg of 
VSVG packaging vectors (Gift of Jiang Lab, MSKCC). Media was replaced after 
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16hrs. 48hrs after transfection, virus-containing supernatant was harvested and 
spun for 10min at 800g before being filtered through 0.45µm filter. For 
transduction of cells, 2mL of the appropriate virus was used to transduce 1 x 105 
cells in the presence of 8µg/mL polybrene. Media was replaced 24hrs later. 48hrs 
after transduction, antibiotic selection was performed with either blasticidin (10-
15µg/mL) or puromycin (2-4µg/mL) for 2-7 days alongside a population of 
untransduced control cells. Selection is deemed completed after untransduced 
control cells were killed by antibiotic selection. After selection, cells were allowed 
to recover in selective antibiotic free media for 72hrs and tested for over-
expression or knockdown of gene of interest by quantitative PCR and Western-
blot where applicable. 
Preparation of adeno-associated virus for in vivo experiments
Adeno-associated viruses was generated by transfection of 30 x 15cm plates of 70% 
confluent 293T cells with 10µg each of pHelper (Cell Biolabs), DJ-Packaging (Cell 
Biolabs), scAAV-miR or scAAV control vector. 16hrs after transfection, the media 
was replaced. 60hrs after transfection, cells were sloughed off by gentle pipetting 
and pelleted by centrifugation. To release viral particles from cells, cell pellets 
were subjected to three cycles of freeze thaw, alternating between a 37 degree 
Celsius water-bath and a dry-ice ethanol bath. After release of viral particles, 
adeno-associated viral particles were purified using Virabind AAV purification 
kit (Cell Biolabs) according to manufacturer’s protocol. Non-viral nucleic acids 
were first digested by incubation of viral supernatant reagent A. Viral particles 
were then captured by affinity beads (reagent B), and loaded onto wash columns. 
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After washing, viral particles were eluted and concentrated using 100kD spin 
columns. Concentrated viral particles were titered using AAV quantification kit 
(Cell Biolabs) according to manufacturer’s protocol. Viral particles were first 
denatured to released viral genomic DNA and viral titer was using the provided 
viral DNA standard and fluorometric DNA binding dye. After quantification, 
viral particles were aliquoted and stored at -80 degree Celsius before use. For 
larger preparation of adeno-associated viral particles, Vector Biolabs provided 
viral preparation services. 
Lenti-miR microRNA library screen 
1 x 106 colon cancer cells were seeded 16hrs prior to the start of experiment. On 
the day of transduction, purified lenti-miR pooled-library viral particles (System 
Biosciences) were used to transduce the seeded colon cancer cells at a low 
multiplicity-of-infection (0.1-1) in the presence of polybrene (8µg/mL) such that 
each individual cell was likely to be transduced by only a single lentiviral 
particle. 48hrs after transduction, transduced cell populations were purified via 
flow cytometry and allowed to recover and expand in vitro. Once sufficient cell
numbers were available (>5 x 106), a portion of the cells was used for intrahepatic 
injection for liver colonization dropout screen. Genomic DNA was extracted 
from the unused population (reference population) of cells using the Qiagen 
DNeasy kit according to manufacturer’s protocol (genomic DNA extraction from 
cells). 4-6 weeks after injection, mice were euthanized, liver nodules were 
harvested and genomic DNA extracted (using protocol for tissue samples). 
Lentiviral inserts, with microRNAs precursors sequences were amplified via 
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PCR using library-specific primers provided by System Biosciences and gel-
purified using Qiagen Gel Purification kit. Genosensor Corporation provided 
microarray preparation and profiling services for quantification of library 
derived microRNA precursors inserts. The raw signal intensities for probe were 
median-normalized. For each cell-line used, biological replicates were performed 
and averaged, with independent library transductions and injection into three 
mice each for each independent transduction. 
LNA mediated inhibition of microRNAs 
Non-targeting control LNA and LNAs targeting miR-483-5p and miR-551a were 
purchased from Exiqon. 10µL of 100µM LNA were transfected into 70% confluent 
cells grown in 15cm cell culture plates using 60µL of Lipofectamine 2000 reagent 
(Life Technologies) in antibiotic free culture media. LNA and Lipofectamine 2000 
reagent were pre-diluted in separate aliquots of 1.5mL of Opti-MEM media (Life 
Technologies) and incubated at room temperature for 5min. After incubation, 
both reagents were mixed gently by pipetting and incubated at room 
temperature for 20min. After incubation, the transfection mix was added drop-
wise to cells to be transfected and the cell culture plate was swirled gently to 
ensure even distribution of transfection reagents. Transfection media was 
removed after 16hrs and replaced with fresh media. 48hrs after transfection, 
transfected cells were used to perform respective assays. 
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Illumina expression beads hybridization and transcriptomic analysis 
To identify transcripts that were regulated by the microRNAs, total RNA was 
extracted from control cell populations and cells over-expressing either 
microRNAs using the miRVANA kit according to manufacturer’s protocol (Life 
Technologies). The RNA was labeled and hybridized onto Illumina HT-12v3 
Expression BeadChip arrays by The Rockefeller University genomics core facility. 
The raw signal intensities were median-normalized. Common putative targets of 
the microRNAs were identified if both microRNAs down-regulate transcript 
levels at least 1.3x fold and confirmed with quantitative real-time PCR validation. 
Putative target genes were further validated to be potential direct targets and 
effectors with dual-luciferase assay and liver metastasis assays. 
Luciferase reporter assay 
The luciferase reporter assay was performed using a Dual-Luciferase Reporter 
Assay Kit (Promega). The full-length 3’-UTR and CDS of CKB were cloned into 
the siCheck2 dual luciferase reporter vector. 2.5 x 104 LS174T cells were seeded in 
quadruplicates for each condition onto 24-well plates and allowed to attach 
overnight before transfection. Cells were co-transfected with either a control 
LNA or LNA targeting miR-483-5p or miR-551a and 100ng of the respective 
siCheck2 dual luciferase reporter vector. 30hrs after transfection, luciferase 
activity was determined using the dual-luciferase assay kit. Cells in each well 
were first washed with gently with 1X PBS and lysed in 100µL of 1X Passive 
Lysis Buffer, with gentle rocking for 30min at room temperature. The cell lysates 
were then collected and spun briefly to clear the cell lysate solutions. 30μL of the 
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cleared solution was then transferred into white opaque 96-well plates. 50μL of 
LARII Reagent was then added to each well and mixed gently by pipetting. The 
bioluminescent signal was read using a microtiter plate reader (Perkin Elmer 
Envision). After the first reading, 50μL of Stop and Glo Reagent was added to 
each well, mixed gently and the resulting bioluminescent signal was read again. 
Cell proliferation and hypoxia survival assay 
For cell proliferation assays, 1 x 105 cells were seeded onto 6-well plates (Falcon) 
in triplicates. Cells were kept in culture for 5 days before collection through 
trypsin digestion and counted using the Cellometer cell-counting machine 
(Nexcelom). Experiments were repeated at least three times. For in vitro hypoxia
assays, 5 x 104 cells were seeded in 24-wells plate and were cultured in 1% 
oxygen in DMEM with 5.6mM glucose for 4 days before counting. Cell counts 
were normalized to that of control conditions. For experiments with 10mM 
phosphocreatine supplementation, 1 x 105 cells were seeded in triplicates in 6-
well plates and cultured in 1% O2 for 4 days before cell counting. For boyden 
chambers co-culture experiments, 5 x 104 cells were seeded on top of transwell 
insert and 5 x 104 cells were seeded at the bottom of the well of the 24 well-plate. 
Cells were cultured in 1% O2 for 4 days before counting. 
Collection of cell culture supernatant 
7.5 x 106 cells were seeded onto 15cm cell culture dishes. After allowing cells to 
attached overnight, cells were washed gently four times with PBS and routine 
culture media was replaced with 12mL serum free media and cell cultured for an 
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additional 24hrs. Supernatant was collected, and centrifuged for 800g for 10min 
to remove debris. Subsequently, 10mL of the supernatant was concentrated using 
a spin column with 10kD cut-off filter to approximately 1mL prior to 
downstream applications. For treatment with brefeldin A, brefeldin A (Biolegend) 
was added to a final concentration of 5μg/mL in the serum-free media and 
supernatant was collected after 6hrs. For treatment with dimethyl-amiloride 
(Sigma-Aldrich), the final concentration was 15nM and supernatant was 
collected after 16hrs. 
Phosphocreatine and ATP measurements 
Cells were cultured routinely (unless otherwise stated) and harvested at 
approximately 70% confluence. On day of measurement, 1 x 106 cells here 
detached from culture dish by trypsin, washed twice in PBS and lysed in 1mL 
ATP assay buffer (Biovision). After vortexing to ensure homogenization, 200μL 
of perchloric acid (Biovision) was added to the cell homogenate. Vortexing was 
performed to ensure complete extraction of proteins, the homogenate was 
incubated on ice for 5min before centrifugation at 15,000g for 3min. 960μL of the 
resulting supernatant was withdrawn and 40μL of neutralization buffer 
(Biovision) was added to the supernatant. The solution was vortexed to ensure 
mixing, and incubate on ice for 5min before centrifugation at 15,000g for 3min to 
spin down any residual precipitate. Triplicate aliquots of 100μL of the cleared 
supernatant were subsequently transferred to a white flat-bottom 96 well 
microplate.  50μL of Vialight assay buffer (Lonza) was added and the mixture 
was incubated at room temperature for 10min. After 10min, 100μL of ATP 
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monitoring reagent (Lonza) was added and a bioluminescent reading was 
performed using a microplate reader (Perkin Elmer Envision). The value of the 
reading corresponds to the relative ATP levels. Subsequently, 5μL of 100mM 
ADP (Sigma-Aldrich) and 50μL of reconstituted rabbit creatine phosphokinase 
(500u/mL) (Sigma-Aldrich) was added and the reaction was allowed to 
completion (10-15min) before a bioluminescent reading was taken. The increase 
in bioluminescent signal corresponds to phosphocreatine levels. 
Western-Blot 
Cell lysates were prepared by lysing cells grown on 10cm plates in 1mL of RIPA 
buffer containing protease inhibitors. Lysate was quantitated using Bio-Rad BCA 
kit. 40µg protein from cell lysates were separated on a 4-12% SDS-PAGE and 
transferred to a PVDF membrane. Membrane was blocked for 1hr in 5% milk in 
PBST (except for FLAG antibody, blocking was performed in 5% BSA in PBST for 
1hr). Antibodies were incubated overnight in 2% milk in PBST at 4 degrees with 
gentle rocking. The CKB antibody was purchased from Abcam (Cat. 38212, 1:400 
dilution). CKB neutralizing antibody was purchased from Abcam (Cat. 48651, 
1:10). (GAPDH antibody was purchased from Genetex (Cat. GTX627408, 1:5000 
dilution). The FLAG antibody was purchased from Sigma (Cat. F3165, 1:2000 
dilution). SLC6a8 antibody was purchased from Abcam (Cat. 62196, 1:1000 
dilution). CD39 antibody was purchased from Abcam (Cat. 127167, 1:1000 
antibody). Horseradish peroxidase-conjugated secondary antibodies were 
purchased from GE Health Sciences and used at a dilution of 1:1000, in 2% milk 
in PBST for 1hr. In between antibody incubation, membranes were washed 3X in 
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PBS, 15mins per wash. Chemiluminescent detection of proteins was performed 
using Pierce ECL plus kit. 
PCR for cloning or genomic DNA amplification 
PCR for cloning or genomic DNA amplification was performed using Phusion 
enzyme (NEB) according to manufacturer’s protocol. Generally 200 to 400ng of 
starting template were used. PCR products were visualized using gel 
electrophoresis, excised and purified using Qiagen gel-extraction kit. Restriction 
digest was performed NEB restriction enzymes, at 37 degree Celsius for 6hrs and 
ligation into appropriate vector performed using NEB T4 ligase, at 16 degree 
Celsius overnight. 
Real-time PCR from archival RNA samples 
For microRNA, cDNA synthesis was performed with 50ng of total RNA using 
the Universal cDNA synthesis kit II (Exiqon, MA) according to protocol. qRT-
PCR LNA primers for miR-551a, miR-483-5p and SNORD44 endogenous control 
was purchased from Exiqon and real-time PCR was performed with SYBR-green 
master mix (Life Technologies, CT). For mRNA, cDNA synthesis was performed 
with 200ng of total RNA using the Superscript III cDNA synthesis kit (Life 
Technologies according to protocol using oligo-dT primers. 
Analysis of publicly available microarray data 
Microarray data from GSE41258 was used to analyze mRNA expression of CKB 
and SLC6A8 from unmatched primary tumor samples and liver metastasis 
samples. Expression was compared using one-sided Mann Whitney U test. 
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Analysis of tissue microarray 
Staining of tissue microarray was performed by New York Presbyterian hospital 
histopathology lab. Each core on the tissue microarray is given a score of 0-3 
based on intensity of staining. Scores of 0 and 1 are interpreted as negative for 
protein expression while scores of 2 and 3 are interpreted as positive staining for 
each core. A tumor sample is considered positive if at least 2 cores (out of 3 
replicate cores) showed positive staining, and is considered negative if cores 
showed 0 and 1 staining intensities, or if only 1 core (out of 3 replicate cores) 
showed staining intensity of 2-3. For each positive sample, the area (% tumor) 
corresponding to each staining intensity was recorded to allow for calculation of 
percentage tumor positivity and a weighted overall staining score (H-score) is 
calculated as (percentage area of 2+ staining x 2) + (percentage area of 3+ 
staining x 3). Individual cores were excluded from the analysis if no tumor was 
present, tumor was predominantly necrotic or falling off the slide or if tumor 
was of signet ring cell morphology due to rarity. A patient sample was not 
included in the analysis if more then one core (out of 3 replicate cores) was 
excluded for reasons above or if only two replicate cores were available and they 
showed discordant results (i.e. one core scored positive and one core score 
negative). 
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Table M.1 | List of Primers used 
miR-551a O/E Fwd CGCATAGGATCCGGAGAACCTTCAGCTTCA
TGTGAC 
miR-551a O/E Rev CGCATAGAATTCGGTCCCTTCCCAGGCTTGG
GGGAG 
miR-483-5p O/E Fwd CGCATAGGATCCCCTGCCCCATTTGGGGGT
AGGAAG 
miR-483-5p O/E Rev CGCATAGAATTCGCTGCCTCCTTCCTCAGAT
GAAAAATGGGC 
miR-551a AAV Fwd CGCATAAGATCTGGAGAACCTTCAGCTTCA
TGTGAC 
miR-551a AAV Rev CGCATACTCGAGGGTCCCTTCCCAGGCTTG
GGGGAG 
miR-483-5p AAV Fwd CGCATACTCGAGCCTGCCCCATTTGGGGGT
AGGAAG 
miR-483-5p AAV Rev CGCATAGCGGCCGCGCTGCCTCCTTCCTCAG
ATGAAAAATGGGC 
miR Control Hairpin GATCCCCGGTGACTTTCTGTAACAATTTCAA
GAGAATTGTTACAGAAAGTCACC 
AAV-Fwd GCTGACCCTGAAGTTCATCTG 
AAV-Rev CACCTTGATGCCGTTCTTCT 
CKB O/E Fwd CGCATAGGATCCATGACGGAGGCGGAGCA
GCAGC 
CKB O/E Rev CGCATAGTCGACTCATTTCTGGGCAGGCAT
GAG GTC 
CKB qPCR Fwd TGAGTTCATGTGGAACCCTCACCT 
CKB qPCR Rev AACTTCTCATGCTTGCCCAGGTTG 
SLC6a8 qPCR Fwd GGCAGCTACAACCGCTTCAACA 
SLC6a8 qPCR Rev CAGGATGGAGAAGACCACGAAG 
GAPDH qPCR Fwd AGCCACATCGCTCAGACAC 
GAPDH qPCR Rev GCCCAATACGACCAAATCC 
FLAG-DEVD-CKB Fwd CGCATAGGATCCATGGATTACAAGGATGAC
GACGATAAGCTGGGCGGCACCGGCAGCGG
CAGCGGCGACGAGGTGGACGGCCCCTTCTC
CAACAGCCACAACGCAC 
FLAG-DEVD-CKB Rev CGCATAGTCGACTCATTTCTGGGCAGGCAT
GAGGTC 
IgK-FLAG-CKB Fwd CGCATAGGATCCATGGAGACAGACACACTC
CTGCTATGGGTACGCTGCTCTGGGTTCCAGG
TTCCACTGGTGACGATTACAAGGATGACGA
CGATAAGCCCTTCTCCAACAGCCACAACGC
AC 
CD39 O/E Fwd CGCATAGGATCCATGGAAGATACAAAGGA
GTCTAACGTGAAG 
CD39 O/E Rev CGCATAGTCGACTATACCATATCTTTCCAGA
AATATGAAGGCTTG 
CKB CDS Luciferase Fwd CGATGCCTCGAGATGCCCTTCTCCAACAGC
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CACAACG 
CKB CDS Luciferase Rev GCGGCCGGCGGCCGCTCATTTCTGGGCAGG
CATGAGGTC 
CKB 3’UTR Luciferase Fwd CGATCGCTCGAGAGCCCGGCCCACACCCGA
C 
CKB 3’UTR Luciferase Rev GCGGCCGGCGGCCGCCAGACGCAGGCAGG
C CAAAACC 
CKB 3’-UTR Mutagenesis 
Forward 
ATGCACCCCTGATGTTCGCAACATGGCGAG
CCCTTAGCCTTG 
CKB 3’-UTR Mutagenesis 
Reverse 
CAAGGCTAAGGGCTCGCCATGTTGCGAACA
TCAGGGGTGCAT 
CKB CDS Mutagenesis 
Forward 
GACAATAAGACCTTCCTGGTGTAAATCAAC
GAGGAGGACCACCT 
CKB CDS Mutagenesis 
Reverse 
CCTTCTGCATGGAGATGGTTCGCAGGTGGTC
CTCCTC 
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Table M.2 | List of shRNA sequences used 
shRNA Sequence 
shCtrl CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTG
CTCTTCATCTTGTTGTTTTTG 
shCKB #3 CCGGCCCAGATTGAAACTCTCTTCACTCGAGTGAAGAG
AGTTTCAATCTGGGTTTTTG 
shCKB #5 CCGGCCGCGGTATCTGGCACAATGACTCGAGTCATTGT
GCCAGATACCGCGGTTTTTTG 
shSLC6a8 #1 CCGGCACGGGAAAGATCGTGTACTTCTCGAGAAGTACA
CGATCTTTCCCGTGTTTTTG 
shSLC6a8 #2 CCGGGCTGGTCTACAACAACACCTACTCGAGTAGGTGT
TGTTGTAGACCAGCTTTTTG 
shSLC6a8 #4 CCGGCTTATTCCCTACGTCCTGATCCTCGAGGATCAGG
ACGTAGGGAATAAGTTTTTG 
shSLC6a8 #5 CCGGATTACCTGGTCAAGTCCTTTACTCGAGTAAAGGA
CTTGACCAGGTAATTTTTTG 
shGAMT CCGGATGGCCATCGCAGCGTCAAAGCTCGAGCTTTGAC
GCTGCGATGGCCATTTTTTG 
! 139!
Sequences of miR-551a and miR-483-5p with flanking genomic sequence in 
adeno-associated viral vector 
miR-551a (with flanking genomic sequence) in AAV 
GGAGAACCTTCAGCTTCATGTGACCCAGAGACTCCTGTATGCCTGGCTCT
GGGAGTACAGAAGGGCCTAGAGCTGACCCCTGCCCTCCGAAGCCCCTGG
GGCACTAGATGGATGTGTGCCAGAGGGTAGTAGAGGCCTGGGGGTAGAG
CCCAGCACCCCCTTCGCGTAGAGACCTGGGGGACCAGCCAGCCCAGCAA
CCCCCTCGCGGCCGACGCCTGAGGCTGTTCCTGGCTGCTCCGGTGGCTGC
CAGAGGGGACTGCCGGGTGACCCTGGAAATCCAGAGTGGGTGGGGCCA
GTCTGACCGTTTCTAGGCGACCCACTCTTGGTTTCCAGGGTTGCCCTGGAA
ACCACAGATGGGGAGGGGTTGATGGCACCCAGCCTCCCCCAAGCCTGGG
AAGGGACCCCGGATCCCCAGAGCCTTTCCCTGCCTATGGAGCGTTTCTCTT
GGAGAACAGGGGGGCCTCTCAGCCCCTCAATGCAAGTTGCTGAG 
miR-483-5p (with flanking genomic sequence) in AAV 
CCTGCCCCATTTGGGGGTAGGAAGTGGCACTGCAGGGCCTGGTGCCAGC
CAGTCCTTGCCCAGGGAGAAGCTTCCCTGCACCAGGCTTTCCTGAGAGGA
GGGGAGGGCCAAGCCCCCACTTGGGGGACCCCCGTGATGGGGCTCCTGC
TCCCTCCTCCGGCTGATGGCACCTGCCCTTTGGCACCCCAAGGTGGAGCC
CCCAGCGACCTTCCCCTTCCAGCTGAGCATTGCTGTGGGGGAGAGGGGG
AAGACGGGAGGAAAGAAGGGAGTGGTTCCATCACGCCTCCTCACTCCTC
TCCTCCCGTCTTCTCCTCTCCTGCCCTTGTCTCCCTGTCTCAGCAGCTCCAG
GGGTGGTGTGGGCCCCTCCAGCCTCCTAGGTGGTGCCAGGCCAGAGTCC
AAGCTCAGGGACAGCAGTCCCTCCTGTGGGGGCCCCTGAACTGGGCTCA
CATCCCACACATTTTCCAAACCACTCCCATTGTGAGCCTTTGGTCCTGGTG
GTGTCCCTCTGGTTGTGGGACCAAGAGCTTGTGCCCATTTTTCATCTGAGG
AAGGAGGCAGC 
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